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Abstract 
PATIENT PORTAL USE AND ITS ASSOCIATION WITH CLINICAL 
OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES 
Ran Sun, PhD, MSN, RN 
University of Pittsburgh, 2019 
Background: The rapid growth of type 2 diabetes mellitus (T2DM) in the United States presents 
significant challenges. Patient portals are promising tools that address the increasing number of 
individuals with T2DM and engage these people in the process of managing their chronic condition. 
Objectives: The purposes of this study were: 1) to describe the portal usage pattern by individuals 
with T2DM over the two-year study period; 2) to identify whether sociodemographic, 
socioeconomic, and clinical characteristics differ between portal users and non-users; and 3) to 
longitudinally examine the effect of portal use on glycemic control in patients with T2DM. 
Methods: This two-year retrospective, observational cohort study utilized data from the 
ambulatory electronic health records (EHR) of the University of Pittsburgh Medical Center 
(UPMC) Physician Services and its ancillary patient portal. The study included adults seen in an 
outpatient setting of UPMC between January 2015 and December 2016. We applied descriptive 
statistics to describe sample characteristics and portal usage patterns. Logistic regression was used 
to examine factors associated with portal use. A propensity score matching (PSM) technique was 
conducted to equate the portal user and non-user groups, and mixed modeling was performed to 
examine the effect of portal use on hemoglobin A1c (HbA1c) over time. Results: Nearly one-third 
of the individuals (n=12,615, 32.9%, 95% CI: [32.3%,33.3%]) with T2DM used the portals. An 
increased portal usage was observed before and after a physician visit, and on weekdays compared 
to weekends (p<0.001). In general, we found associations of age, race, income, and the number of 
chronic conditions with portal usage, and several other predictors modified these effects (ps<0.05). 
After PSM, both groups showed a non-linear decline of HbA1c over time (p<.001), and the portal 
users (n=4,924) demonstrated a greater decrease and better maintenance than the non-users 
(n=4,924, p<.001). Conclusions: Our findings highlight the promising effect of a patient portal on 
clinical glycemic control in persons with T2DM. Disparities in patient portals need to be addressed 
to bridge the existing gaps in diabetes outcomes. Future study should explore mechanisms through 
which the portal contributes to better clinical outcomes to guide evidence-based portal design and 
implementation. 
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1.0 PROPOSAL 
1.1 SPECIFIC AIMS 
Diabetes affected 30.2 million U.S. adults in 2017 (Centers for Disease Control and 
Prevention, 2017a) and the prevalence of diabetes is expected to increase to nearly 55 million by 
2030 (Rowley, Bezold, Arikan, Byrne, & Krohe, 2017). Type 2 diabetes mellitus (T2DM) is the 
most common form of diabetes, accounting for 90% to 95% of all cases (Centers for Disease 
Control and Prevention, 2017b). To optimally manage their T2DM, patients need to be equipped 
with knowledge, skills, and ability to consistently perform self-care activities, including adopting 
a healthy eating plan, performing regular physical activity, and taking medication (Powers et al., 
2017). Moreover, effective diabetes care requires integrated efforts by patients and healthcare 
providers, characterized by greater coordination, communication over time and between visits, 
tailored services to each patient’s needs and preferences, and shared patient-provider responsibility 
(Singer et al., 2011). The current healthcare system, however, does not meet all of the needs of 
persons with chronic conditions (Priester, Kane, & Totten, 2005).  
Emerging technologies are transforming healthcare delivery and creating opportunities to 
manage chronic conditions for a larger population. Since the passing of the Health Information 
Technology for Economic and Clinical Health Act in 2009, healthcare organizations have widely 
adopted health information technology, such as patient portals, to meet patient needs. Patient 
portals, also referred to as tethered personal health records (PHR), are a secure online website 
providing patients access to their own health information. This technology is becoming 
increasingly popular in healthcare systems. By 2015, nearly 70% of the U.S. hospitals had 
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provided patients access to view, download, and transmit their health information online (Office 
of the National Coordinator for Health Information Technology, 2015). Patient portals hold the 
potential to improve patient-provider communication and engage patients and families in 
healthcare, which can lead to improved clinical outcomes, especially for management of chronic 
diseases such as diabetes, hypertension, and cancer (Sorondo, Allen, Fathima, & Bayleran, 2016). 
Researchers focusing on persons with diabetes have investigated the effects of patient 
portal use on glycemic control and found inconsistent findings. Using a randomized controlled 
trial (RCT) design, Ralston et al. examined the impact of using an online portal for diabetes 
management on changes in HbA1c among individuals with uncontrolled glycemic control. 
Compared to the usual care group, the intervention group had a greater reduction in HbA1c at 12 
months (Ralston et al., 2009). Four other RCTs did not find an improved HbA1c at the end of the 
study compared to the usual care group (Grant et al., 2008; McCarrier et al., 2009; Tang et al., 
2013; Vugt et al., 2016). In addition to these RCTs, three observational studies examined the 
association of portal use with HbA1c. Tenforde et al. found a significantly lower HbA1c among 
portal users than non-users (Tenforde, Nowacki, Jain, & Hickner, 2011). Harris et al. demonstrated 
that frequent use of electronic messaging was associated with HbA1c < 7% (relative risk [RR] = 
1.36, 95% CI:1.16–1.58) (Harris, Haneuse, Martin, & Ralston, 2009). A more recent study 
observed that persons with uncontrolled blood glucose (i.e., HbA1c ≥ 7%) at baseline were more 
likely to achieve HbA1c < 7% at follow-up if they used the secure messaging for two years (odds 
ratio [OR] = 1.24, 95% CI:1.14–1.34) and more (OR = 1.28, 95% CI:1.12–1.45) (Shimada, 
Allison, Rosen, Feng, & Houston, 2016); however, this study examined only certain features 
within the portal and did not investigate the overall effect of the patient portal.  
In recent years, patient portals have received greater attention and gained rapid acceptance 
by patients and providers; yet few current studies have described the usage pattern of the portal by 
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persons with T2DM. Moreover, our review of the literature revealed that no studies have 
longitudinally examined the association between patient portal use and HbA1c. In an effort to 
address these issues, we propose a study using data from the ambulatory electronic health records 
(EHR) of the University of Pittsburgh Medical Center (UPMC) physician services to describe 
portal use by individuals (N=38,399) with T2DM between January 2015 and December 2016. 
Additionally, we examined whether the portal use was associated with HbA1c outcome over time. 
Hence, the Primary Specific Aims were:  
Aim 1: To describe the pattern of portal use by individuals with T2DM during the period 
of January 2015 to December 2016 
1a: To describe the portal features used by individuals and how frequently each feature was 
used (i.e., the number of users and the total volume) 
1b: To describe the frequency of portal use during weekdays as compared to on weekends and 
in relation to clinic visits 
Aim 2: To identify predictors (e.g., age, gender, race, education, income, insurance type, 
number of chronic conditions) of portal use (use vs. non-use) 
The Exploratory Aim is: 
Aim 3: To longitudinally examine the association of portal use with HbA1c among 
individuals with uncontrolled glycemic control (HbA1c > 7%) 
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1.2 BACKGROUND AND SIGNIFICANCE 
1.2.1  Background 
1.2.1.1 Diabetes prevalence, complications and economic burden in the United States (U.S.) 
A 2017 CDC report revealed that approximately 30.3 million people of all ages, or 9.4% 
of the U.S. population, have diabetes (Centers for Disease Control and Prevention, 2017a). The 
prevalence is projected to increase by 54% to more than 54.9 million Americans by 2030 (Rowley 
et al., 2017). Among all diabetes cases, nearly 90% to 95% are T2DM (Centers for Disease Control 
and Prevention, 2017b). Optimal glycemic control effectively minimizes the complications; 
however, nearly half of patients did not achieve their glycemic control as measured by hemoglobin 
A1c (HbA1c) at less than 7%  (Carls, Huynh, Tuttle, Yee, & Edelman, 2017; Menon & Ahluwalia, 
2015). Poorly controlled T2DM increases the risk for developing serious macro- or microvascular 
complications, including heart disease, visual impairment, renal disease, and lower-extremity 
amputation (Fowler, 2008; Gerstein & Werstuck, 2013). These complications have led to 
significant economic consequences. More than 20% of healthcare spending is for the care of 
individuals with diabetes (Centers for Disease Control and Prevention, 2016). The medical and 
societal costs related to diabetes is projected to increase from $408 billion in 2015 to over $622 
billion by 2030 (Rowley et al., 2017). In summary, T2DM is a growing problem facing U.S. 
healthcare systems, and it is critical to identify strategies to better manage the increasingly large 
proportion of the population with diabetes. 
1.2.1.2 Management of type 2 diabetes 
Diabetes management is burdensome, requiring affected patients to acquire the knowledge, 
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skills, and ability to consistently perform self-care activities (e.g., healthy eating, regular physical 
activity, adherent medication taking), attend regular clinic visits, and manage other comorbid 
conditions (American Diabetes Association, 2017; Powers et al., 2017). Moreover, effective 
diabetes care requires integrated efforts by patients and healthcare providers, characterized by 
greater coordination, communication over time and between visits, tailored services to each 
patient’s needs and preferences, and a shared patient-provider responsibility (Singer et al., 2011). 
The current healthcare system, however, is structured to diagnose and treat acute medical 
conditions rather than chronic conditions. Thus, it limits the system’s ability to fully meet the needs 
of persons with chronic conditions (Anderson, 2010). Considering the growing prevalence and the 
extensive demands on the current healthcare system to manage such a complex chronic disease, it 
is imperative to identify innovative approaches to address these challenges.  
1.2.1.3 Patient portals and their functionality 
The emerging technologies are transforming healthcare delivery and creating opportunities 
to manage chronic conditions for a larger proportion of the population. Healthcare organizations 
have commonly adopted electronic health record (EHR) systems and incorporated a patient portal 
as an essential component in their system. Patient portals are often tethered to an institution’s 
electronic health record. The functionalities offered by each patient portal vary across systems. 
Most portals allow patients to view lab results, schedule appointments, request medication refills, 
receive visit summaries, and electronically communicate with healthcare providers. More 
advanced portals enable individuals with multiple chronic conditions to record their symptoms and 
test results (such as blood glucose or blood pressure readings) that can be seen by providers (Office 
of the National Coordinator for Health Information Technology, 2013). More recently, patients are 
able to access their patient portal information from their tablets or smartphones. With this instant 
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access to health record data, patients may become more engaged with their health conditions and 
proactive about questions and concerns related to their diseases. 
1.2.1.4 Regulation and Meaningful Use 
Several Centers for Medicare and Medicaid Services (CMS) programs promote the use of 
patient portals. The Health Information Technology for Economic and Clinical Health Act 
(HITECH) of 2009 launched the EHR use incentive program, often referred to as “Meaningful 
Use,” wherein those physicians and healthcare systems that meet the criteria for the three stages 
of Meaningful Use would receive financial incentives. Stage 2 of the Meaningful Use incentive 
program requires patients to 1) view online, download, and transmit information about a hospital 
admission and 2) communicate electronically using secure messaging on relevant health 
information (Healthcare Information and Management Systems Society, 2014). Eligible 
professionals must provide 50% of patients with access to an electronic copy of their health 
information, and 5% of their patients must view, transmit, or download their health information. 
Additionally, providers must implement notifications for follow-up appointments and identify 
clinically relevant health information to more than 10% of their patients with two or more 
appointments in the preceding two years (Centers for Medicare and Medicaid Services, 2014).  
 In the current era of the Medicare Access and CHIP Reauthorization Act (MACRA), 
healthcare systems place greater emphasis on patient engagement and quality of care. Under one 
of the two MACRA reimbursement tracks, the Merit-based Incentive Payment System (MIPS), 
physicians are rated based on their performance categories: advancing care information (ACI), 
quality, improvement activities, and cost. Each of the performance categories is considered 
dependent heavily on features provided in patient portal technology, such as receiving reminders 
of services due and secure messaging with providers (Rodocker, 2016). 
7 
1.2.1.5 Patient portal adoption by healthcare providers and patients 
These CMS payment incentive programs have been successful in boosting the adoption 
rate. Healthcare organizations are committed to increasing the number of patients who use the 
portal and developing a comprehensive approach to having patients registered and supporting their 
use of the portal. The percentage of hospitals that have provided patients with the capability to 
view, download, and transmit their health information online has risen exponentially from 10% in 
2013 to 69% in 2015 (Office of the National Coordinator for Health Information Technology, 
2015). A recently conducted survey with 1,756 healthcare leaders revealed that 90% of healthcare 
organizations offer portal access to patients (Medical Group Management Association, 2018). 
Physicians have made similar progress in expanding their capability for supporting portal use with 
their patients. For example, 64% of physicians exchanged secure messages with their patients, 
63% provided access to patients to view medical record, 41% permitted patients to download their 
health record, and 19% electronically transmitted their health record to a third party (The Office 
of the National Coordinator for Health Information Technology, 2015).  
 As more healthcare providers offer these services, patients have a growing interest in 
registering for patient portals to perform routine medical-related tasks and interact with providers. 
Patient enrollment in some well-established health systems is high. Kaiser Permanente, an 
institution that has used portals for over a decade, reported that over 70% of eligible adult members 
registered to use its patient portal since the third quarter of 2015 (T. Garrido, Raymond, & 
Wheatley, 2016). It is estimated that the percentage of people who will adopt a PHR is expected 
to exceed 75% by 2020 (Ford, Hesse, & Huerta, 2016).  
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1.2.1.6 Conceptual framework 
The proposed study is based on the Chronic Care Model (CCM), which represents a 
comprehensive model of care to meet the needs of the growing numbers of people with chronic 
disease in a primary care setting (E. Wagner, 1998). The 2015 position statement by the American 
Diabetes Association has recommended that diabetes care should be concentrated on the 
components of CCM to ensure productive patient-provider interactions between informed patients 
and a prepared care team (American Diabetes Association, 2015).  This model of care posits four 
main components that facilitate the productive interactions: 1) self-management support, 2) 
delivery system design, 3) decision support, and 4) clinical information system within community 
and health systems. A systematic review of 16 studies from 1999 to 2011 using CCM-based 
interventions demonstrated positive clinical outcomes for managing diabetes in primary care 
settings (Stellefson, Dipnarine, & Stopka, 2013). 
 The CCM model was further modified by Gee et al. in 2015, which offered insight into the 
role of health information technology (e.g., mobile health, patient portals) in self-management 
support for people with chronic conditions (Gee, Greenwood, Paterniti, Ward, & Miller, 2015). 
Gee et al. conducted a review of 95 papers on technology and chronic disease self-management 
support. The results strengthened the contribution of eHealth tools to the CCM and suggested that 
patient outcomes could be further enhanced by adding eHealth education and a complete feedback 
loop (Gee et al., 2015). 
1.2.1.7 Literature review of patient portals for diabetes management 
Patient portals enable continuous patient-centered care and are intended to improve patient-
provider communication, engage patients and families in healthcare, and result in improved 
clinical outcomes, especially for management of chronic diseases such as diabetes (Sorondo et al., 
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2016). Patient portals have been considered to potentially fill the unmet needs related to chronic 
disease management and improve chronic care by facilitating continuous patient education and 
ongoing communication regarding symptoms, medication and side effects (Umejei & Wiafe, 
2010). Many patients’ needs could potentially be met more quickly and at a lower cost through 
patient portals. 
 Earlier randomized controlled trials (RCT) were conducted to examine the impact of 
patient portals on blood glucose control among individuals with T2DM revealing inconsistent 
results. A 12-month study by Tang et al. evaluated the online disease management system 
developed by the Palo Alto Medical Foundation for individuals with uncontrolled diabetes (i.e., 
A1c ≥ 7.5%). The researchers found a significantly reduced A1c in the intervention group (n = 
193) compared to the usual care group (n = 189) at 6 months (-1.32% vs. -0.66%, p < 0.001), but
not at 12 months (-1.14 vs. -0.95%, p = 0.133) (Tang et al., 2013). Another RCT (N = 83) 
conducted by Ralston et al. at the University of Washington General Internal Medicine Clinic 
demonstrated a greater decrease in glycated hemoglobin (GHb) in the intervention group than the 
usual care group at 12 months (change -0.9% vs. 0.2%, p = 0.01) (Ralston et al., 2009). However, 
two RCTs failed to observe significant changes in HbA1c over time or an overall difference 
between groups. Grant et al. included 244 persons with diabetes from the Partners HealthCare 
system and assigned them to one of the two study arms containing different PHR content. No 
significant difference was observed in HbA1c between the study arms after a 1-year follow-up 
(Grant et al., 2008). A more recent study conducted at the VU University Medical Center in the 
Netherlands used the PHR e-Vita for persons with T2DM (N = 132) in a primary care setting. The 
2-group 6-month study aimed to test the effect of a personal health record including a self-
management support program with and without coaching on diabetes-related outcomes, including 
diabetes self-care, diabetes-related distress, emotional wellbeing, and health status (e.g., HbA1c). 
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The results demonstrated a minimum impact of utilizing a PHR including self-management 
support on diabetes-related outcomes (Vugt et al., 2016).    
Three observational studies examined the association of portal use with HbA1c. Two of 
the three studies investigated a certain single feature (e.g., secure messaging, online medication 
refill) within the portal. Shimada et al. conducted a retrospective study of veterans with diabetes 
registered for the MyHealtheVet patient portal. The individuals with uncontrolled glycemia (i.e., 
HbA1c ≥ 7%) at baseline tended to achieve glycemic control (i.e., HbA1c < 7%) after two (OR = 
1.24, 95% CI: 1.14–1.34) or more years of secure messaging use (OR = 1.28, 95% CI: 1.12–1.45); 
however, the online medication refill feature was not associated with glycemic control (Shimada 
et al., 2016). A cross-sectional study focusing only on the secure messaging feature revealed that 
frequent use of secure messaging (over 12 threads) was associated with controlled blood glucose 
(RR = 1.36, 95% CI: 1.16–1.58) among Group Health Cooperative patients (Harris et al., 2009). 
Finally, a study that examined the overall effect of the PHR on 10,746 adults at the Cleveland 
Clinic demonstrated that an incremental increase in portal use was associated with a minimum 
decrease in HbA1c (0.02%, p < 0.01) (Tenforde et al., 2011). 
There are major gaps in the literature on patient portals for diabetes management. First, 
most of the existing studies used cross-sectional study design, thus limiting their ability to identify 
or relate events to certain exposure and establish the sequence of events (Caruana, Roman, 
Hernández-Sánchez, & Solli, 2015). Few studies have longitudinally examined the association 
between patient portal use and HbA1c. Second, the small sample sizes in most of the studies make 
them difficult to infer conclusions about the non-linear associations (i.e., quadratic or cubic 
changes over time) and to detect interactions among predictors, while relatively larger sample sizes 
enable more complicated statistic models that capture and convey richer information. Last, in 
recent years, patient portals have received greater attention and gained rapid acceptance by patients 
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and providers, especially after the launch of the Meaningful Use incentive program; yet, the 
majority of studies were conducted earlier, and few current studies have described the usage 
pattern of the patient portal in patients with T2DM. The proposed study addresses these gaps. 
1.2.2  Significance and Innovations 
1.2.2.1 Significance 
The Institute of Medicine (IOM) called for a redesign of the healthcare delivery system 
toward continuous, coordinated care, and a leveraging of information technology, especially for 
chronic conditions that require frequent monitoring and ongoing support (Institute of Medicine, 
2001). The use of patient portals could address these demands for ongoing care for chronic 
illnesses such as diabetes, but the evidence is limited as to how to use this technology to improve 
diabetes-related outcomes. It is important, therefore, to understand which persons use the portal, 
how they use it, and whether this usage will affect the clinical outcomes for persons with diabetes. 
Thus, the proposed study is significant because the findings could do the following:  
• Provide a timely and detailed description of the actual use of patient portal features offered
as part of an EHR by an integrated healthcare organization
• Reveal disparities in access to the patient portal between patient groups to further identify
strategies for reducing disparities and, consequently, improving diabetes outcomes;
• Apply to other patient populations using patient portals as an innovative and promising
approach to support chronic disease management; and
• Expand knowledge about the effectiveness of our healthcare system to support disease
management pertaining to the broader domain of using technology as a tool in chronic
disease management.
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1.2.2.2 Innovation 
The proposed study is innovative because it does the following: 
• Leverages the existing EHR data to provide evidence on the use of information technology 
for chronic conditions, specifically the use of patient portals to manage diabetes 
management; and  
• Applies the propensity score matching to mimic certain characteristics of randomized 
controlled trials and then longitudinally examines the association between portal use and 
HbA1c using available repeated measures data. 
 
1.3 RESEARCH DESIGN AND METHODS 
1.3.1  Study design  
This study was a two-year retrospective, observational cohort study. The data being used 
were from the ambulatory electronic health records of UPMC Physician Services and its ancillary 
source of the patient portal.  
 MyUPMC, previously called UPMC HealthTrak, is the name of the patient portal system, 
which is linked to the EpicCare (MyChart product) EHR system. This web-based portal has been 
available to UPMC patients since 2007. The service, which is free to all patients18 years of age or 
older, is also available for mobile devices using the MyChart application. Patients can perform a 
wide variety of actions through the portal: accessing portions of their EHRs by linking them to 
their medical history and test results; renewing prescriptions; managing appointments; viewing 
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billing statements and making payments; and manually uploading blood pressure or glucose 
readings. By 2014, nearly 240,000 patients had registered an account with MyUPMC. 
1.3.2  Sample 
UPMC is a non-profit, integrated health system located in Western Pennsylvania 
containing more than 30 academic, community, and specialty hospitals and over 600 doctors’ 
offices and outpatient sites. For this study, the cohort of individuals with DM was determined by 
the presence of the International Classification of Diseases, Ninth Revision (ICD-9) diagnosis 
codes of 250.* and the International Classification of Diseases, 10th Revision (ICD-10) diagnosis 
codes of E11.* between January 2015 and December 2016. To accurately identify individuals with 
DM in the UPMC dataset, two or more indicators, as suggested from a previous study, need to be 
applied (Zgibor et al., 2007). Therefore, we included in this study only patients who had any 
HbA1c assessments and were prescribed with diabetes medications during the study period. 
Patients who potentially had type 1 diabetes (T1DM) were excluded as indicated by the following 
either 1) having only ICD-9 codes for T1DM (250.x1 or 250.x3) with no ICD-9 codes for T2DM 
diagnosis, or 2) being younger than 40 years old and taking only insulin (Lo-Ciganic, Zgibor, 
Ruppert, Arena, & Stone, 2011). Furthermore, patients were removed if they were 1) new to the 
portal as determined by having no record of portal activities before 2015, 2) newly diagnosed with 
T2DM during the study period based on patients’ problem list, and 3) had only one specialty care 
visit over the study period, since these patients may not be ongoing consumers of the UPMC health 
system. To longitudinally examine the association between portal use and HbA1c in individuals 
with uncontrolled blood glucose, we only included patients who had two or more HbA1c 
assessments with their initial HbA1c value equal to or greater than 7%. 
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1.3.3  Measures 
Patient portal use      Information captured regarding portal access included the date of 
access and the type of activities performed within the portal. The type of activities performed by 
users was grouped into six categories: view lab results, view medical summary, electronic 
messaging, manage appointment, update and share medical information, and renew prescriptions. 
For each category, we counted the number of users who have used that feature for 1-9 times, 10-
19 times, more than 20 times during the 2-year study period. Also, we calculated the frequency of 
the overall portal use as well as the frequency of use for each type of activity over time. To address 
Aim 2 and Aim 3, we analyzed the portal use as a binary variable (any use vs. non-use). 
 Sociodemographic and socioeconomic characteristics      Sociodemographic factors 
extracted from the EHR were age (years), gender (male or female), race (white, black, or other), 
and type of insurance (government programs, commercial, self-insured, or other). We linked the 
following neighborhood-level socioeconomic ratio variables from the US Census Bureau’s 2011-
2015 American Community Survey (five-year estimates)(US Census Bureau, 2015) to each patient 
via their five-digit zip code: income (the median household income in the past 12 months in 2015 
inflation-adjusted dollars); educational attainment (the percentage of residents who have attained 
a bachelor’s degree or higher); and urbanization (the percentage of urban residents in a specific 
zip code).  
 Clinical characteristics      Glycemic control was measured using HbA1c, an indicator of 
long-term glycemic control that reflects mean glycemia over the previous 8 to 12 weeks. The 
repeatedly measured HbA1c and the date of measurements over the two-year study period were 
extracted from laboratory test data. We identified the initial HbA1c date and value and the 
frequency of HbA1c tests for each patient. For two or more HbA1c tests performed less than two 
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weeks apart, we kept only the first measurement of HbA1c in our analysis because 1) HbA1c is an 
indicator of average glucose in the past two or three months and 2) the HbA1c values measured 
within a short time span were close or identical.  
The number of chronic conditions was determined from the encountered diagnosis for each 
patient. We used the Chronic Condition Indicator (CCI), found in the Clinical Classification 
System (CCS) developed as part of the Healthcare Cost and Utilization Project (HCUP) sponsored 
by the Agency for Healthcare Research and Quality (AHRQ) (Agency for Healthcare Research 
and Quality, 2016), to determine whether an ICD code represents a chronic condition or non-
chronic one. We then calculated a new continuous-type ratio variable–the number of chronic 
conditions–by adding up the number of distinct chronic conditions in addition to diabetes for each 
patient during the study period.   
 Medication information was retrieved from the medication prescriptions. Insulin use and 
oral agents for T2DM were identified using the therapeutic classes according to the American 
Hospital Formulary Services (AHFS) Pharmacologic-Therapeutic Classification System 
(American Society of Health-System Pharmacists, 2016). The number of distinct diabetes 
medications prescribed to each patient was calculated. Insulin use was a binary variable (yes/no) 
representing whether or not the patient was prescribed insulin. 
Patient weight and height were measured at each clinical visit. To determine a patient’s 
body mass index (BMI), we used the mode of all height assessments and the median weight of 
each patient. The BMI was calculated as (weight in pounds*703) / (height in inches)2. 
 Healthcare utilization       The date of outpatient visits and the specialty (e.g., internal 
medicine, cardiology, endocrinology) of visits were retrieved. Two types of visits were used in 
this study and included visits to an endocrinologist (yes/no) and visits to a primary care physician 
(PCP, the frequency of visits during the study period). Additionally, the documented telephone 
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contacts of patients with healthcare providers over the 2-year period were received, and the number 
of telephone contacts was then calculated for each patient. 
 Most of these variables, which were related to sociodemographic and socioeconomic 
characteristics (e.g., age, gender, race, education, household income) and clinical characteristics 
(e.g., number of chronic conditions, number of distinct diabetes medications, insulin use), served 
as descriptors or predictors. For Aim 3, we matched portal users and non-users on variables (e.g., 
BMI, insulin use, visit an endocrinologist) that were significantly associated with the HbA1c 
outcome.   
1.3.4  Statistical analysis plan  
Statistical analyses were conducted using R Statistical Software (R version 3.5.1 and R 
Studio 1.1.456) for Mac. 
1.3.4.1 Sample size justification   
This study used existing data from the electronic health record over the two-year period; 
thus, the sample size was fixed (N = 38,399) after applying the cohort selection criteria. When 
describing the pattern of portal use by individuals with T2DM in terms of the portal features used 
and how frequently each feature was used (i.e., the number of users and the total volume of 
accesses) and the frequency of portal use in relation to clinic visits (Aim 1), proportions and means 
were estimated with margins of error (in terms of the half-width of two-sided confidence interval) 
of .005 (conservatively assuming a base proportion 0.50) and 0.009σ (where σ is the population 
standard deviation of the particular continuous type variable of interest), respectively, with 95% 
confidence. 
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 When examining patient predictors of portal use (Aim 2) with a total sample of 38,399, of 
which 12,615 (32.9%) were expected to be portal users, unadjusted odds ratios (ORs) for portal 
use as small as 1.043 for continuous type predictors (that are linear in the logit and follow a normal 
distribution) could be detected with 90% power at an adjusted, testwise significance level of 0.01 
for two-sided hypothesis testing. Adjusted ORs for portal use as small as 1.053 for the continuous 
type predictors could be derived given the obtained R-Square of 0.34 due to the multiple regression 
of the independent variable on the other independent variables in the logistic regression. When 
considering categorical type predictors, such as race and sex, small detectable effect sizes in terms 
of the OR were again expected. For example, for patient’s sex, where 19,140 (49.8%) were 
expected to be female, unadjusted ORs for portal use as small as 1.087 (1.108 for the adjusted 
ORs) could be detected with 90% power at a significance level of 0.01 for two-sided hypothesis 
testing, while for patient’s race, where most (n=32,706, 85.2%) were expected to be white, 
unadjusted ORs for portal use as small as 1.124 (1.155 for the adjusted ORs) could be detected 
with 90% power a significance level of 0.01 for two-sided hypothesis testing. 
Exploratory Aim. This specific aim is purely exploratory; however, in a previous study a 
small effect size (in terms of the standardized mean difference, d = 0.214) was observed in HbA1c 
between portal users (7.0 ± 1.3, n = 4,036) and non-users (7.3 ± 1.5, n = 6,710) (Tenforde et al., 
2011). With this small effect size in mind and with 12,615 portal users and 25,784 portal non-
users, we would have >> 99.9 power to detect an effect as small as 0.214 at a significance level of 
0.05 for two-sided hypothesis testing. For the reduced sample size of the propensity-score matched 
portal-users (n=4,924) and non-users (n=4,924), we would also achieve >>99.9 power at a 
significance level of 0.05. 
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1.3.4.2 Preliminary analysis procedures   
We assessed for data accuracy, univariate and bivariate data distributions, univariate and 
multivariate outliers, amount and pattern of missing data, and the underlying statistical 
assumptions given the planned analysis strategies. A validation process was performed before the 
data analysis. We checked the accuracy of the outcome variable HbA1c by displaying the 
frequency of all values to identify problematic entries (e.g., >14.0, @13, 8.3/8.7, coded as -2), and 
also implausible values (i.e., HbA1c < 3.5%, HbA1c > 20%, to be recoded as -3). Both problematic 
entries and implausible values were treated as missing values in the analysis. A similar approach 
was applied to weight data. Patient weight was repeatedly assessed in every clinic visit. Values 
that fell within the acceptable range (i.e., weight > 50 lbs. and weight < 1000 lbs.), but were likely 
erroneous when compared to the patient’s other weight measures, were identified by calculating 
within-patient z scores for that individual. An absolute z score greater than 3.29 was identified as 
a problematic entry (recoded as -2). We displayed the frequency of BMI values, and further 
examined the presence of clinically implausible BMI values (i.e., BMI < 15 kg/m2 or BMI > 100 
kg/m2).  
After identifying missing values, we screened for possible patterns in these missing values 
to determine whether or not data were missing at random. Little’s test was performed to assess 
whether data were missing completely at random (MCAR). Listwise deletion was used if data were 
MCAR and the amount of missing data were not affecting the precision when estimating 
parameters and statistical power when testing hypotheses. If data appear to be not missing at 
random (NMAR), we explored the sensitivity of the results, assuming different patterns of data 
missingness.   
Univariate and multivariate outliers were assessed based on the variables’ levels of 
measurement. For nominally scaled categorical variables (e.g., gender, race), the frequency 
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distribution was displayed. For ratio variables, we examined the shapes of data distributions via 
histograms, checked the tails of the distribution, and inspected boxplots for extreme values. Also, 
we calculated z scores on that continuous type variable, with absolute values of z scores greater 
than |3.29| indicating univariate outliers. Multivariate outliers were identified by examining a 
bivariate scatterplot between each pair of variables and computing a Mahalanobis distance for the 
set of variables of interest.  
The underlying the statistical assumptions (i.e., linearity between variables/linearity of 
logit of all continuous type independent variables with the logit of the probability of being a portal 
user, independence of observations, homoscedasticity of error variance, normality of residuals, 
absence of multicollinearity) for statistical modeling were assessed. To check the normality of raw 
data distribution, histograms were used to graphically display the distribution of the variables. We 
mainly focused on graphical methods (i.e., histogram or pie chart) rather than inferential statistics 
given the large sample size we had in our study. Appropriate data transformations (e.g., log base 
10 or square root) were considered when data deviate from normality. Bivariate scatterplots were 
used to examine the independence of cases by plotting the key variables of interest versus the 
subject’s identification number. Linearity between any pair of variables was assessed by displaying 
the bivariate scatterplot. Any multicollinearity issues were revealed by bivariate correlations and 
variance inflation factors (VIF). A Levene test and bivariate scatterplots were examined for 
homoscedasticity. 
1.3.4.3 Data analysis procedures 
Data analysis plan for Aim 1. The descriptive statistics (e.g., line chart) of the overall 
portal use, as well as the use of each feature (e.g., secure messaging, lab results, appointment 
management) over time were reported (Aim 1a). To describe the portal use around an office visit 
  
 20 
 
for Aim 1b, we created a two-week window before and after a physician visit. We selected the first 
visit for each patient as an example and illustrated the number of users within the four-week 
window. The number of users for each day within the window was also delineated in relation to 
visits. Comparison of portal usage between weekdays (5 days) and weekends (2 days * 2.5) was 
performed using the Wilcoxon signed-rank test for the two-related samples. Tables and graphs 
(e.g., line chart) were displayed as appropriate.  
Data analysis plan for Aim 2. Binary logistic regression was used to investigate the 
association between patient characteristics and the use of patient portal (use vs. non-use). Patient 
characteristics examined included age, gender, race, education, income, urbanization, type of 
health insurance, number of chronic conditions, insulin use and number of diabetes medications 
for T2DM, initial HbA1c, the frequency of HbA1c tests, and the total number of outpatient visits 
and telephone contacts over the study period. All two-way interactions between the predictor 
variables were assessed. Outliers were detected by Pearson residuals or deviance residuals through 
index plots. Further checking for influential cases was performed by calculating the Cook’s 
distance. Unadjusted and adjusted odds ratios with their corresponding 95% confidence intervals 
(CI) were reported. We used the likelihood ratio test to examine whether our model was 
significantly better than the intercept-only model. The Hosmer–Lemeshow test was used to assess 
the model goodness of fit.  
For model evaluation, we split our dataset into two parts, using the dataset containing 75% 
of the sample for model training and the remaining 25% of the sample for model testing. The 
backward elimination procedure was used to remove non-significant variables (p ≥ 0.5) and to 
generate a parsimonious model. The evaluation of the model was performed in the testing dataset 
by calculating the model sensitivity and specificity. Furthermore, we determined the percentage of 
cases that were accurately classified based on the fitted model in the testing dataset with respect 
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to the observed classification. We plotted a receiver operating characteristic (ROC) curve to 
identify the optimal threshold value, and we determined the percentage of the area under the ROC 
curve (AUC) to indicate the model discrimination. 
Data analysis plan for Aim 3. For Aim 3, we investigated the changes in HbA1c over 
time between portal user group and non-user group. Patients with uncontrolled glycemic control 
were included as determined by the initial HbA1c value great than 7%. To perform longitudinal 
data analysis, we further limited our cohort to patients with two or more HbA1c assessments.  
The propensity score matching technique was applied to balance the differences in 
demographic and clinical covariates between patient portal users and non-users. This approach 
allows an unbiased estimation of the treatment effect in the context of observational studies 
(Rosenbaum & Rubin, 1983). The propensity score for each patient was generated using a logistic 
regression model, including all covariates (age, gender, race, health insurance type, household 
income, educational level, urbanization of a zip code, BMI, number of HbA1c tests, initial HbA1c 
value, number of distinct glucose-lowering medications, insulin use, and visits to an 
endocrinologist) that were associated with the outcome HbA1c as identified in the literature. One-
to-one nearest-neighbor matching without replacement was used (Austin, 2011a). Evaluation of 
the balance of each confounding variable between portal user and non-user group was performed 
by determining the standardized absolute means difference (SMD) with a caliper of 0.2 (Austin, 
2009, 2011b).  
Linear mixed-effect modeling or random coefficient modeling was used to investigate the 
changes in HbA1c over time between portal users and non-users. We included time and portal use 
group as fixed effects and treated the intercepts for the subject and by-subject random slope for 
the effect of HbA1c as random effects. Time was treated as a continuous variable indicating the 
days since the study started. Both linear and non-linear functions of time were considered. We first 
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examined the interaction between group and time, if there was a significant interaction effect on 
the outcome, the interaction was included in the model; otherwise, we excluded it and investigated 
only the main effects of group and time on HbA1c values. We controlled for the covariates that 
were not balanced after the propensity score matching between the two groups. For fitting the 
model, the variance-covariance structure of the repeated assessments was determined such as 
variance components, compound symmetry or unstructured covariance. The dependent variable 
HbA1c was measured repeatedly at unequal intervals, thus we considered covariance structures 
that allow for unequal spacing (e.g., spatial covariance structure) and assessed using standard 
information criteria (e.g., AIC, BIC). The restricted maximum likelihood method (REML) was 
used for model fitting and parameter estimation. A likelihood ratio test was used to compare nested 
models; a significant test means that the more complex model has a better fit than the simpler 
model. Estimated regression coefficients with confidence intervals, standard error, values of test 
statistics, and p-values were reported. 
 
1.4 POTENTIAL LIMITATIONS OF THE PROPOSED PROCEDURES AND 
ALTERNATIVE APPROCHES 
Using secondary EHR data within healthcare systems presents a large number of 
challenges and limitations. These data are commonly collected from a variety of practitioners from 
different service specialties and geographic locations, which commonly result in erroneous data 
that are incomplete (reduced data frequency), inaccurate (out-of-range values or based on different 
units of measurement), and inconsistent (mismatch between hospital units or within the same unit).  
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In clinical trials, data tend to be collected at fixed time intervals during the study period; 
whereas data for studies using EHRs are captured when patients are seen or when tests are 
performed. For example, the primary outcome HbA1c is not assessed at regular intervals, and the 
frequency of HbA1c measurements is expected to vary across patients. The standards of medical 
care in diabetes, as suggested by the American Diabetes Association, are that HbA1c testing should 
be performed regularly for all patients with diabetes; for patients who meet treatment goals, HbA1c 
testing needs to be obtained at least twice a year, but quarterly HbA1c testing is recommended for 
patients who do not meet glycemic goals (American Diabetes Association, 2017). However, these 
decisions are sometimes subject to the patient’s and physician’s preference. 
Ideally, EHRs capture and integrate data on all aspects of care over time; in reality, existing 
data in one EHR system rarely contains information generated from visits to other clinical or non-
clinical settings or lab results done during those visits. Patients may seek care from other 
physicians using paper records or different EHR platforms that are not linked; as a result, patients’ 
data included in our study may not be complete. Moreover, data on some patients are not available 
for the entire study period due to 1) the variability when clinics or physicians transitioned into 
EHR documentation–recent adoption in EHR may result in a lack of historical data, or 2) patients 
who leave the system making it difficult or impossible to observe their status.  
Additionally, the point-of-care (POC) HbA1c testing results are less accessible and not 
included in our data analysis. The POC HbA1c testing is sometimes performed during a patient 
encounter as a supplement clinical laboratory test. By doing this, providers can receive immediate 
results that minimize the delay in diabetes treatment, and reduce the need for additional office 
visits to implement clinical decisions. However, these results were not captured electronically in 
the EHRs. 
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Using EHR data, some variables included in the statistical model may not accurately reflect 
the variables we want to include. For example, we calculated the years since the first diabetes 
diagnosis as noted in the patient’s problem lists, which may not reflect the true diabetes onset date. 
According to an article by the American Health Information Management Association (AHIMA), 
the problem list should support documentation of the patient’s historical information and identify 
the time of occurrence and resolution of the condition (AHIMA Work Group, 2011). However, 
the date of diabetes diagnosis information may not be accurate or updated timely in the EHRs. 
The absence of certain data fields in the EHR limits the variables we studied and the 
number of explanatory factors we considered. Medication adherence can greatly affect glycemic 
control outcomes; yet, the longitudinal medication record in the EHR often fails to provide 
information regarding patient adherence to medication-taking. This occurs because institutions 
commonly track medications that are prescribed, they do not monitor whether prescriptions were 
filled or medications were taken by the patients.  
Finally, we are cautious that our sample may be biased. We included only patients who had 
at least one visit to UPMC physician services or clinics from 2015 to 2016, which may not be 
representative of those with no visits during the two-year study period. Usually, the most health-
conscious people visit their providers more often than less health-conscious peers in the 
community.  
1.5 RESEARCH PARTICIPANT RISK AND PROTECTION 
The proposed study used existing data from the ambulatory electronic health records and 
the UPMC patient portal; no screening, recruitment, or follow-up of human subjects occurred. 
  
 25 
 
Data were requested through the Center for Assistance in Research using eRecords (CARe). An 
honest broker work for CARe assisted with the de-identification of protected health information 
by removing the patient’s name, address, and other identifiers. The study protocol was submitted 
to the University of Pittsburgh Institutional Review Board (IRB) for an exempt review, and IRB 
approval (#PRO16120082) was received on December 19, 2016, before obtaining the data. 
 As an analysis using de-identified existing data, the subjects received no direct benefit from 
the proposed study. Instead, the findings and knowledge gained provided an understanding of 
portal usage pattern by patients with T2DM, patients' characteristics associated with portal use, 
and the impact of portal use on glycemic control. 
  
  
 26 
 
2.0 MANUSCRIPT 1: PATIENT PORTAL USE IN DIABETES MANAGEMENT: 
LITERATURE REVIEW 
2.1 ABSTRACT 
Background: Health information technology tools (e.g., patient portals) have the potential 
to promote engagement, improve patient-provider communication, and enhance clinical outcomes 
in the management of chronic disorders such as diabetes mellitus (DM). Objectives: The aim of 
this study was to report the findings of a literature review of studies reporting patient portal use by 
individuals with type 1 or type 2 DM (T2DM). We examined the association of the patient portal 
use with DM-related outcomes and identified opportunities for further improvement in DM 
management. Methods: An electronic literature search was conducted using PubMed and 
PsycINFO databases. The keywords used were “patient portal*,” “web portal,” “personal health 
record,” and “diabetes.” Inclusion criteria included (1) published in the past 10 years, (2) used 
English language, (3) restricted to age ≥18 years, and (4) available in full text. Results: This review 
included 6 randomized controlled trials, 16 observational, 4 qualitative, and 4 mixed-methods 
studies. The results of these studies revealed that 29% to 46% of patients with DM have registered 
for a portal account, with 27% to 76% of these patients actually using the portal at least once during 
the study period. Portal use was associated with the following factors: personal traits (e.g., 
sociodemographics, clinical characteristics, health literacy), technology (e.g., functionality, 
usability), and provider engagement. Inconsistent findings were observed regarding the association 
of patient portal use with DM-related clinical and psychological outcomes. Conclusions: Barriers 
to use of the patient portal were identified among patients and providers. Future investigations into 
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strategies that engage both physicians and patients in the use of a patient portal to improve patient 
outcomes are needed. 
 
  
 
2.2 INTRODUCTION 
DM is a significant public health problem that is associated with many debilitating health 
conditions. Prevalence data indicate that approximately one of every ten adults in the United States 
has DM with predictions that the number will triple by 2050 (Centers for Disease Control and 
Prevention, 2010). The economic burden of DM and its complications to the U.S. healthcare 
system is enormous. One in four healthcare dollars is spent for the care of people with DM 
(American Diabetes Association, 2018). Thus, the steady increase in the prevalence of DM and 
the substantial associated costs make this one of the most pressing public health concerns in the 
U.S. 
Effective DM management requires continuous collaboration between individuals and 
their providers (Singer et al., 2011), yet the infrastructure of current health delivery systems does 
not fully support the needs of patients with chronic conditions (Anderson, 2010). A call has been 
sounded to redesign the care delivery systems in order to improve chronic disorder care (Institute 
of Medicine, 2001). The Chronic Care Model (CCM) was developed in 1998 to reorganize care 
delivery to improve functional and clinical outcomes for people with chronic disorders (E. H. 
Wagner et al., 2001). A primary focus of the CCM is on creating productive interactions between 
informed patients and a prepared care team (E. H. Wagner et al., 2001). To achieve this, patients 
need to have the knowledge and skills to make informed decisions, and care teams need to be able 
to provide relevant patient information, resources, and decision support at the point of encounter. 
Health information technologies, such as patient portals, can facilitate these activities within 
healthcare systems.  
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Patient portals, often referred to as tethered personal health records (PHR), provide online 
platforms for patients access to their health information from a health organization’s electronic 
health record (EHR). Patient portals were widely adopted by healthcare organizations in the late 
1990s, and gained greater attention when the Medicare and Medicaid incentive programs for 
Electronic Health Record (a.k.a. “Meaningful Use”) implementation was initiated in 2011 
(Irizarry, DeVito Dabbs, & Curran, 2015). Today, the PHR adoption rate by consumers is rapidly 
increasing. It is estimated that the percentage of people who will have a PHR is expected to exceed 
75% by 2020 (Ford et al., 2016). Patients can perform a variety of medical-related tasks within the 
portal. For example, most portals permit patients to view laboratory results, receive visit 
summaries, manage appointments, and electronically communicate with healthcare providers. 
More advanced portals enable individuals to record their symptoms and test results, such as blood 
glucose or blood pressure readings, data that can be viewed for decision-making and changes in 
therapy by providers (Office of the National Coordinator for Health Information Technology, 
2013). Healthcare organizations have commonly adopted patient portals as an essential strategy to 
provide patient-centered care and engage patients for the purpose of improving clinical outcomes.  
2.2.1  Purpose 
Given the continuous increase in the prevalence of DM and the increasing development of 
patient portal applications, a review of the literature on the current use of patient portals in 
supporting patients with DM can be informative. In this review, we identified studies that used 
qualitative or quantitative methods to describe the state of science in the use of patient portals for 
diabetes management. Specifically, we evaluated the use of patient portals by patients with DM, 
including the portal functionalities, predictors of portal use, and the effects of portal use on 
diabetes-related outcomes. These findings provide opportunities for further approaches to improve 
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DM management through the use of a patient portal. 
2.3  METHODS 
2.3.1  Search Strategies 
Electronic literature searches were conducted through PubMed and PsycINFO databases. 
Keywords included “patient portal*,” “web portal,” “personal health record,” and “diabetes.” 
Additional articles were searched by identifying similar articles in PubMed and manually 
reviewing the bibliography of published papers in relevant articles. The literature search was 
limited to publications in the English language and peer-reviewed articles, but no restrictions as to 
the country in which the study was conducted were imposed. 
2.3.2  Inclusion and exclusion criteria 
Articles selected were based on the following inclusion criteria: (1) published in the past 
10 years (2007-2017), (2) used the English language, (3) study participants were adults (i.e., age 
≥18 years), and (4) available in full text. Studies using both quantitative and qualitative methods 
were included in this review. The focus of the selected articles was a patient population of adults 
with either type 1 diabetes mellitus (T1DM) or T2DM. Studies were excluded if the portal was 
designed for parents of children with diabetes. 
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2.3.3  Data extraction 
The initial search from PubMed and PsycINFO retrieved 128 articles after filtering out 11 
articles that did not meet the inclusion criteria. We removed 8 duplicates, which reduced the 
number to 120 articles for review of the title and abstract. The assessment of these 120 articles 
resulted in a further removal of 74 articles, including 63 that were not relevant, five articles that 
focused on children, and six articles that applied mobile apps for diabetes management. Thus, a 
review of full text was conducted on 46 articles based on the aforementioned inclusion criteria, 
and 17 were excluded because of the use of stand-alone Web portals that were not connected to 
any healthcare organizations; also two review papers were excluded. We later added three 
additional articles by searching the bibliography of previously published literature reviews. 
Therefore, a total of 30 articles were included in our study (see Figure 1), including six randomized 
controlled trials (RCTs), 16 observational studies, four qualitative studies, and four mixed-
methods studies. RCTs and observational studies were summarized based on the following 
categories: authors and country, study aims and design, sample size and retention, intervention 
(only for experimental studies), PHR features, measures, and findings. Studies that used qualitative 
methods or mixed methods were summarized based on study aims, study design, sample, PHR 
features, measures or questions, and findings (see Tables 1 and 2; Appendix 1). 
2.3.4  Quality Assessment 
The quality of the reviewed studies that used quantitative methods was assessed using the 
evidence grading system developed by the American Diabetes Association. An evidence grade of 
A, B, C, or E was assigned depending on the quality of the evidence. A grade A evidence was 
considered optimal because it is derived from large, well-designed clinical trials or meta-analyses; 
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it is estimated to have the best chance to improve outcomes when applying the treatment to the 
appropriate population. Grade B ratings indicated supporting evidence from well-conducted cohort 
studies or case-control studies. Grade C ratings indicate supporting evidence from poorly 
controlled or uncontrolled studies. A separate category E was applied to papers reporting expert 
opinions or clinical experience when there was no evidence from clinical trials. 
 
 
 Figure 1. Flow Diagram for Paper Selection Process 
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2.4 RESULTS 
2.4.1  Description of included studies 
We reviewed 30 studies focusing on 13 different portals from three countries—10 from the 
United States, two from the Netherlands, and one from Canada. Of these 13 portals, five were 
designed for patients with diabetes and functioned as a component in Web-based diabetes 
management programs. These five DM-specific patient portals were from the Palo Alto Medical 
Foundation, VA Boston Healthcare System, University of Washington General Internal Medicine 
Clinic, the VU University Medical Center, and the Diamuraal of the Netherlands. Almost half of 
the included studies (n=13) focused on patients with T2DM, one on patients with T1DM, six 
included both types, and ten did not specify. 
Of all the studies included, six were RCTs (Fonda, McMahon, Gomes, Hickson, & Conlin, 
2009; Grant et al., 2008; McCarrier et al., 2009; Ralston et al., 2009; Tang et al., 2013; Vugt et al., 
2016) (Table 1). These studies examined the effect of a DM-specific patient portal on diabetes-
related outcomes. The sample sizes for the RCTs ranged from 77 to 415, with the number of 
subjects in two studies being less than 100 (McCarrier et al., 2009; Ralston et al., 2009) and in one 
study more than 400 (Tang et al., 2013). The study duration in the five RCTs was 12 months 
(Fonda et al., 2009; Grant et al., 2008; McCarrier et al., 2009; Ralston et al., 2009; Tang et al., 
2013), with the duration of the remaining RCTs being 6 months (Vugt et al., 2016). Of six RCTs, 
five reported a retention rate range of 50.4% to 89.2% and employed an intention-to-treat approach 
to handle protocol deviations (Grant et al., 2008; McCarrier et al., 2009; Ralston et al., 2009; Tang 
et al., 2013; Vugt et al., 2016). These six RCTs studied an array of diabetes-related outcomes, 
including glycated hemoglobin (HbA1c) or glycohemoglobin (GHb), systolic blood pressure 
(SBP) and diastolic blood pressure (DBP), body mass index (BMI reported as kg/m2), total 
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cholesterol, and low-density lipoprotein (LDL). The psychological outcomes that were examined 
included diabetes-related distress and diabetes-related self-efficacy. 
 
Table 1. Randomized Controlled Trials Examining Patient Portal for Diabetes Management 
Authors and 
Country 
Study aims, 
design, and level 
of evidence 
Sample and 
retention 
Patient portal features Intervention Outcomes 
(portal 
related) 
Findings 
van Vugt et 
al (2016), 
Netherlands  
 
  
2-group study, 6-
month 
randomized 
controlled trial 
(RCT) to study 
the uptake and 
effects of e-Vita 
with a self-
management 
support program 
(SSP) and 
personalized 
coaching for Ps 
with type 2 
diabetes mellitus 
(T2DM) 
 
Evidence: Grade 
A 
N=132; males: 
59.1%; white: 
91%; age: 67.9 (SD 
10.4) years; body 
mass index (BMI): 
30.2 (SD 5.2); 
glycated 
hemoglobin 
(HbA1c): 6.6%; 
retention: 
Coaching group 
(CG): 43.9%; 
noncoaching group 
(NCG):59.1% 
e-Vita (diabetes 
mellitus [DM]-
specific) by VU 
University Medical 
Center allows patients 
(Ps) to access diabetes 
education; access data 
from electronic 
medical records 
(EMRs) of primary 
care physicians 
(PCPs); receive 
messages from 
providers; receive SSP  
CG (n=66):  
Personal health 
record 
(PHR)+SSP+ 
coaching 
 
NCG (n=66):  
PHR+SSP  
HbA1C, BMI, 
systolic blood 
pressure 
(SBP), 
diastolic 
blood pressure 
(DBP), 
cholesterol, 
diabetes self-
care, diabetes-
related 
distress, and 
PHR and SSP 
use 
Intention-to-treat (ITT) 
was applied. PHRs were 
assessed by 128 Ps, of 
which 59 Ps never 
returned to the PHR. The 
use declined over time. 
The SSP was used by 5 
Ps in the CG and 1 
patient in the NCG 
group, 3 of whom asked 
a coach for feedback. Ps 
recently diagnosed 
actively used the SSP; 
no differences were 
observed on outcome 
measures between 
baseline (BSL) and 6 
months for the 2 groups. 
Tang et al 
(2013), 
United States   
2-group study, 12-
month RCT to 
evaluate a Web-
based disease 
management 
system by Ps with 
uncontrolled 
T2DM 
 
Evidence: Grade 
A 
N=415; 
Intervention (Int) 
vs Control (Con): 
males: 58.9% vs 
61%; white: 60% 
vs 58%; age: 54 
(SD 10.7) vs 53.5 
(SD 10.2) years; 
weight: 215.3 (SD 
49.4) vs 218.4 (SD 
51.3) pounds; 
HbA1c: 9.24 (SD 
1.59) vs 9.28 (SD 
1.74); Retention: 
87% 
Web-based diabetes 
management system 
(DM specific) by Palo 
Alto Medical 
Foundation allows Ps 
to monitor glucose 
remotely; view 
summary report; 
document nutrition and 
exercise; record 
insulin; communicate 
with the health team; 
receive advice; 
personalized education 
Int (n=202): 
access to Web-
based disease 
management 
system for 
diabetes; Con 
(n=213): usual 
care 
HbA1c, BP, 
low-density 
lipoprotein 
(LDL), 
healthcare 
utilization, 
diabetes 
knowledge, 
diabetes 
treatment 
satisfaction, 
and 
depression 
screening 
ITT was applied. Int had 
reduced HbA1c at 6 
months (−1.32% Int vs 
−0.66 Con, P<.001), but 
not at 12 months. The Int 
had better LDL control 
at 12 months (P=.001), 
but no difference for BP, 
or weight. Ps in the Int 
had a lower distress 
score (P<.001), better 
knowledge of glucose 
testing (P=.004), better 
understanding of 
diabetes (P<.001), 
greater treatment 
satisfaction (P<.001). 
No differences were 
noted in the depression 
screening or health care 
utilization.  
Fonda et al 
(2009), 
United States   
2-group study, 12-
month RCT to 
examine changes 
in Problem Areas 
in Diabetes 
(PAID), and its 
association with 
use of an internet-
based diabetes 
care management 
(IBCM) program;  
N=104; males: 
99%; white: 
76.7%; age: 60.9 
(SD 10.3) years; 
HbA1c: 9.9 (SD 
0.9%); Retention 
not reported 
IBCM (DM specific) 
by VA Boston 
Healthcare System 
allows Ps to transmit 
BP and glucose data 
from devices; view BP 
and glucose data; 
message care 
managers; access 
diabetes education 
Int (n=52): 
access to the 
IBCM program; 
Con (n=52): 
usual care 
Diabetes 
distress 
(PAID), and 
pattern of 
usage 
The decline in PAID 
score was significant for 
sustained users of the 
portal but not for 
nonusers in the Int 
group. Sustained users 
(n=27) had lower PAID 
scores at baseline.   
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Evidence: Grade 
A 
McCarrier et 
al (2009), 
United States   
2-group study, 12-
month RCT to test 
whether a diabetes 
case management 
program can 
improve glycemic 
control and self-
efficacy in adults 
with T1DM;  
 
Evidence: Grade 
A 
N=77; males: 
67.5%; white: 
96.1%; age: 37.3 
[8.09] years; 
HbA1c: 8%; 
Retention: 83% 
Web-based program 
(DM specific) by 
University of 
Washington (UW) 
General Internal 
Medicine Clinic allows 
Ps to view EHR data; 
upload glucose 
readings; enter 
medication, nutrition, 
and exercise; create 
action plans; access 
education 
Int (n=41): usual 
care+Web-based 
case 
management pro
gram; Con 
(n=36): usual 
care 
HbA1c, 
diabetes-
related self-
efficacy, and 
usage 
ITT was applied. A 
nonsignificant decrease 
in HbA1c in the Int 
compared with the Con 
group (−0.48%, 95% CI 
−1.22 to 0.27) between 
groups. The Int group 
had an increase in self-
efficacy compared with 
the Con group (95% CI 
0.01-0.59, P=.04). The 
log-in rate was 61%, and 
averaged 3.3 log-ins per 
patient. Emails were sent 
by 44% users, with a 
mean of 5.0 messages. 
Ralston et al 
(2009), 
United States  
2-group study, 12-
month RCT to test 
Web-based care 
management of 
glycemic control 
using a shared 
EMR in Ps with 
T2MD;  
 
Evidence: Grade 
A 
N=83; Int vs Con: 
females: 47.6% vs 
51.2%; white: 
89.7% vs 73% 
(P=.06); age: 57 vs 
57.6 
Glycohemoglobin 
(GHb): 8.2% vs 
7.9%; Retention: 
89.2% 
Web-based diabetes 
support program (DM 
specific) by UW 
General Internal 
Medicine Clinic allows 
Ps to access EHR data; 
communicate with 
providers; send 
glucose readings; enter 
exercise, diet, and 
medication data; 
access education 
Int (n=42): usual 
care+Web-based 
case 
management 
program; Con 
(n=41): usual 
care 
GHb, total 
cholesterol, 
SBP, DBP, 
health care 
utilization, 
and usage 
ITT was applied. More 
change in GHb among 
the Int group compared 
with the Con group at 12 
months (change −0.7%, 
P=.01). SBP, DBP, total 
cholesterol levels, and 
use of in-person health 
care services did not 
differ between groups. 
EHR was accessed 76%, 
69% emailed, and 33% 
entered data. Number of 
page views was not 
associated with GHb 
improvement. 
Grant et al 
(2008), 
United States   
2-group study, 12-
month RCT to 
evaluate the 
impact of a PHR 
for T2DM;  
 
Evidence: Grade 
A 
N=244; Int vs Con: 
females: 43% vs 
56% (P=.04); 
white: 93% vs 84% 
(P=.04); age: 58.8 
vs 53.3 years 
(P<.001); HbA1c: 
7.3% vs 7.4%; 
Retention: 50.4% 
Patient Gateway by 
Partners Health care 
system allows Ps to 
update registration 
information; send 
messages; confirm 
appointments; request 
prescription refills; 
access DM modules 
  
Int (n=126): 
access to a DM-
specific PHR (ie, 
review 
mediations, and 
access decision 
support and care 
plans); Con 
(n=118): non-
DM-specific 
PHR 
HbA1c, BP, 
and LDL 
ITT was applied. More 
Ps in the Int group had 
DM treatment adjusted 
compared with the Con 
group (53% vs 
15%; P<.001). There 
was no difference in 
HbA1c between groups 
(Int vs Con: 7.1% vs 
7.2%) after 1 year. BP 
and LDL showed similar 
patterns at BSL and 
follow-up between 
groups.  
 
There were 16 observational studies identified (Bredfeldt, Compton-Phillips, & Snyder, 
2011; Cho et al., 2010; Harris et al., 2009; Lyles et al., 2013; Roelofsen et al., 2014; Ronda, 
Dijkhorst-Oei, Gorter, Beulens, & Rutten, 2013; Ronda, Dijkhorst-Oei, & Rutten, 2014, 2015, 
Sarkar et al., 2010, 2011, 2014; Shimada et al., 2016; Sieverink, Kelders, Braakman-Jansen, & 
Van Gemert-Pijnen, 2014; Tenforde et al., 2011; Wald et al., 2009; Weppner et al., 2010), which 
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included three retrospective cohort studies (Sarkar et al., 2014; Shimada et al., 2016; Weppner et 
al., 2010) and 13 cross-sectional studies (Appendix 1). The sample sizes of these studies were 
variable; seven studies had more than 10,000 participants (Harris et al., 2009; Lyles et al., 2013; 
Sarkar et al., 2010, 2011, 2014; Shimada et al., 2016; Tenforde et al., 2011), and five studies had 
less than 1000 (Bredfeldt et al., 2011; Cho et al., 2010; Ronda et al., 2015; Sieverink, Kelders, et 
al., 2014; Wald et al., 2009). The data obtained only from the EHR were examined in 7 studies 
(Bredfeldt et al., 2011; Harris et al., 2009; Sarkar et al., 2014; Shimada et al., 2016; Sieverink, 
Kelders, et al., 2014; Tenforde et al., 2011; Weppner et al., 2010), and nine studies combined data 
collected from the EHR and patient surveys (Cho et al., 2010; Lyles et al., 2013; Roelofsen et al., 
2014; Ronda et al., 2013, 2014, 2015, Sarkar et al., 2010, 2011; Wald et al., 2009). The association 
between patient portal use and diabetes-related outcomes was investigated in five studies; one of 
the studies examined the overall portal use (Tenforde et al., 2011), whereas the other four studies 
investigated only certain features within the portal, such as secure messaging (Bredfeldt et al., 
2011; Harris et al., 2009; Shimada et al., 2016) or medication refills (Sarkar et al., 2014; Shimada 
et al., 2016). The remaining 11 studies examined the usage of the patient portal and factors 
associated with portal use (Cho et al., 2010; Lyles et al., 2013; Roelofsen et al., 2014; Ronda et 
al., 2013, 2014, 2015, Sarkar et al., 2010, 2011; Sieverink, Kelders, et al., 2014; Wald et al., 2009; 
Weppner et al., 2010). 
Qualitative methods were used in four studies (Hess et al., 2007; Sieverink, Braakman-
Jansen, et al., 2014; Urowitz et al., 2012; Zickmund et al., 2008), and four additional studies used 
mixed methods to address the benefits and barriers of using patient portals (Bryce et al., 2008; 
Mayberry, Kripalani, Rothman, & Osborn, 2011; Osborn, Mayberry, Wallston, Johnson, & Elasy, 
2013; Wade-Vuturo, Mayberry, & Osborn, 2013) (Table 2). Focus group was used in six studies 
(Bryce et al., 2008; Hess et al., 2007; Mayberry et al., 2011; Osborn et al., 2013; Wade-Vuturo et 
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al., 2013; Zickmund et al., 2008), of which four also used patient surveys (Bryce et al., 2008; 
Mayberry et al., 2011; Osborn et al., 2013; Wade-Vuturo et al., 2013). The sample sizes in the six 
studies using focus groups ranged from 39 to 75 (Bryce et al., 2008; Hess et al., 2007; Mayberry 
et al., 2011; Osborn et al., 2013; Wade-Vuturo et al., 2013; Zickmund et al., 2008). In one study, 
semistructured interviews with 11 primary care nurses were conducted (Sieverink, Braakman-
Jansen, et al., 2014). Another study conducted telephone interviews with 17 patients and collected 
qualitative data using open-ended questionnaires from 64 providers (Urowitz et al., 2012). 
Table 2. Qualitative or Mixed Methods Studies on Patient Portal for Diabetes Management 
Authors 
and 
Country 
Study aim Study 
design 
Sample Portal features  Measures or 
Questions  
Findings  
Sieverink 
et al 
(2014), 
Netherland
s  
To explore 
factors 
associated with 
diffusion of a 
personal health 
record (PHR) for 
patients with 
type 2 diabetes 
mellitus 
(T2DM) in 
primary health 
care workers 
Semistruct
ured 
interview 
with 
primary 
care nurses: 
qualitative 
N=11 
 
e-Vita (diabetes 
mellitus [DM]-
specific) by the 
Diabetes Center 
in Zwolle 
allows patients 
(Ps) to access 
diabetes 
education; 
access EMR 
data; receive 
messages from 
providers 
1. What are the 
reasons for 
using a PHR? 
2. What 
training do you 
receive? 
3. How to 
embed PHR in 
your daily 
routine? 
4. What are the 
barriers and 
facilitators for 
embedding 
PHR in daily 
routine? 
5. What are 
your 
expectations? 
Practice nurses indicated 
barriers for using a PHR: lack 
of integration with work 
routines, time constraints, and 
experience usability problems. 
Osborn et 
al (2013), 
United 
States  
To understand 
Ps with T2DM 
who use 
MyHealthAtVan
derbilt (MHAV) 
and reasons for 
use and nonuse, 
how users are 
using a portal to 
manage 
medications, and 
explore ideas for 
functionality 
improvement 
Focus 
groups and 
medical 
chart 
review: 
mixed 
methods 
N=75; 
females: 
67%; 
white: 
63%; 
age: 56.9 
(SD 8.8) 
years 
MHAV by 
Vanderbilt 
University 
Medical Center 
(VUMC) allows 
Ps to access 
EHR data; 
message 
providers; 
manage 
appointments; 
assess risks; 
access 
education 
1. Do you use 
MHAV or not? 
How and why? 
2. What could 
be added to 
MHAV to help 
manage 
medications? 
3. What do you 
think about an 
email reminder 
to refill or dose 
reminders?  
Users were more likely to be 
white, have higher incomes, 
and be privately insured. 
Reasons for nonuse: unaware 
of the portal (n=3), no access to 
a computer (n=3), and helped 
by a family member (n=1). 
Users used the portal to request 
prescription refills and view 
medication list, and Ps were 
enthusiastic about the idea of 
adding refill reminder 
functionality, alerting 
providers to fill or refill 
nonadherence, and providing 
side effects and interactions. 
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Wade-
Vuturo, et 
al (2013), 
United 
States 
To explore how 
Ps with T2DM 
use and benefit 
from secure 
messaging 
within a patient 
portal  
Focus 
group and 
patient 
survey: 
mixed 
methods 
N=54; 
females: 
65%; 
white: 
76%; 
age: 57.1 
(SD 8.4) 
years; 
body 
mass 
index 
(BMI): 
34.4 
(10.2); 
HbA1c: 
7.0 (SD 
1.4) 
MHAV by 
VUMC allows 
Ps features same 
as above 
HbA1c, self-
reported 
frequency of 
use, benefits 
and barriers to 
use messaging 
Greater use of messaging to 
schedule an appointment was 
associated with patients’ 
glycemic control (r=−.29, 
P=.04). Benefits of messaging: 
improved patient satisfaction, 
enhanced efficiency and 
quality of face-to-face 
visits, and access to care. 
Barriers to use messaging: 
negative experiences with 
messaging. Ps’ assumptions 
about providers’ 
opinion and instruction.  
Urowitz et 
al (2012), 
Canada 
To evaluate the 
experience of Ps 
with T1DM or 
T2DM and 
providers using 
a Web-based 
diabetes 
management 
portal 
Telephone 
interview 
and open-
ended 
questionnai
re: 
qualitative  
Ps 
(n=17); 
females: 
53%; 
providers 
(n=64)  
Patient portal by 
the Waterloo 
Wellington 
Local Health 
Integration 
Network allows 
Ps to access DM 
education; 
access EHR 
data  
Telephone 
interview with 
Ps and open-
ended 
questionnaires 
with providers 
17 Ps were interviewed. 
Facilitators of disease 
management: increase 
awareness of their disease, 
access to educational 
information, and promote 
behavior change. Barriers to 
portal use: poor usability, not 
useful, challenges with 
physician engagement, and 
lack of understanding. 
Recommendations for portal 
improvements: more Web-
based tutorial about the portal 
content, improve usability.  
Mayberry 
et al 
(2011), 
United 
States 
To examine the 
role of health 
literacy, 
numeracy, and 
computer 
literacy on usage 
of a patient Web 
portal (PWP) in 
Ps with T2DM 
Focus 
group and 
patient 
survey: 
mixed 
methods 
N=75; 
females: 
68%; 
white: 
47%; 
age: 56.9 
(SD 8.8) 
years 
MHAV by 
VUMC allows 
Ps features same 
as above 
Health literacy, 
numeracy, 
computer 
literacy, self-
report usage of 
PWP and 
health 
information 
technology 
(HIT) 
Lower health literacy was 
associated with less use of a 
compute for searching diabetes 
medications or treatments, but 
not usage of a PWP. Numeracy 
and computer literacy were not 
associated with PWP use. 
Family members’ support 
facilitated Ps usage of both 
PWP. 
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Bryce et al 
(2008), 
United 
States  
To rate the 
potential or 
actual 
usefulness of 15 
features of a 
Web-based 
portal for 
diabetes 
management  
Focus 
group and 
patient 
survey: 
mixed 
methods 
Preportal 
group 
(n=21) vs 
Portal-
user 
group 
(n=18): 
nonwhite
: 33% vs 
22%; 
age: 53 
(SD 13) 
vs 55 
(SD 11) 
HealthTrak by 
University of 
Pittsburgh 
Medical Center 
(UPMC) allows 
Ps to access 
EMR data; 
schedule 
appointments; 
message 
providers; 
access 
education; 
logbooks  
The study 
asked how the 
portal affected 
management 
of diabetes, Ps’ 
experiences in 
using the portal 
and 
communicatin
g with 
physicians 
Features rated most favorably 
were: calculator to 
estimate blood glucose control 
(74%), appointment reminder 
(74%), email to health team 
(74%), personal tracking logs 
(69%), and scheduling (69%). 
More patients from the 
preportal group than the portal-
users group favored personal 
logs (P=.02) and opportunities 
to form interest groups 
(P=.03).  
Zickmund 
et al 
(2008), 
United 
States 
To examine the 
impact of the 
provider-patient 
relationship on 
interest in using 
the patient portal  
Focus 
group: 
qualitative 
N=39; 
white: 
72%; 
males: 
52%; 
age: 54 
(SD 12) 
HealthTrak by 
UPMC allows 
Ps features same 
as above 
Topics 
included the 
relationships 
with providers, 
and feedback 
on the patient 
portal 
Interest in the portal was linked 
to dissatisfaction with provider 
responsiveness, unable to 
obtain medical information, 
and logistical problems. 
Disinterest in the portal was 
linked to satisfaction with the 
provider communication, 
difficulty in using the portal, 
and fear of losing connections 
with providers. No patient 
identified email 
communication through the 
portal was helpful 
Hess et al 
(2007),Uni
ted States [ 
To assess the 
impact of 
HealthTrak on 
patient-provider 
communication 
during 
September 
2004-January 
2007 
Focus 
groups: 
qualitative 
N=39; 
males: 
51%; 
white: 
72%; 
age: 54 
(SD 12) 
years 
HealthTrak by 
UPMC allows 
Ps to features 
same as above 
Discussion 
around living 
with diabetes, 
desired 
information 
about diabetes, 
current sources 
of information 
about diabetes, 
doctor-patient 
communicatio
n, and reaction 
to the portal 
The number of patient visits or 
telephone calls received did not 
change, but the number of 
HealthTrak messages 
increased. Participants felt that 
the system enhanced 
communication. Having access 
to laboratory tests was 
preferred. The became 
frustrated when test results 
were not released, or messages 
not answered by providers.  
 
2.4.2  Features provided in patient portals 
Features offered in patient portals varied across systems. Most portals allowed patients to 
access a component of the EHR data (e.g., visit summary, medical history, physical examination 
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results, lab results), receive general health education, request prescription refills, and communicate 
with healthcare providers. In the DM-specific portals, patients were able to perform more activities 
such as wirelessly uploading their blood glucose readings assessed via home-monitoring devices 
(Fonda et al., 2009; McCarrier et al., 2009; Ralston et al., 2009; Ronda et al., 2015; Tang et al., 
2013). The education provided in these DM-specific portals was specifically related to patients’ 
conditions and prescribed medications (Fonda et al., 2009; Grant et al., 2008; McCarrier et al., 
2009; Ralston et al., 2009; Tang et al., 2013). A few portals also enabled patients to enter lifestyle 
data such as diet and exercise (McCarrier et al., 2009; Ralston et al., 2009; Shimada et al., 2016; 
Tang et al., 2013). In four RCTs, the interventions included access to the portal and assigned case 
managers (nurses, dietitians, or pharmacists) to assist patients in using the Web-based portal, 
responding to messages, reviewing blood glucose values and food intake, and adjusting 
medications as appropriate (Fonda et al., 2009; McCarrier et al., 2009; Ralston et al., 2009; Tang 
et al., 2013). 
2.4.3  Patient usage of the portal 
The percentage of patients with diabetes who registered for a portal account ranged from 
29% to 46% (Harris et al., 2009; Roelofsen et al., 2014; Sarkar et al., 2010; Sieverink, Braakman-
Jansen, et al., 2014). Among patients with portal accounts, 27% to 76% actually logged on to the 
portal at least once (Fonda et al., 2009; Roelofsen et al., 2014; Ronda et al., 2014; Sarkar et al., 
2010, 2011; Sieverink, Kelders, et al., 2014). However, 50% (3/6) of these studies indicated a 
response rate of less than 50% (Roelofsen et al., 2014; Ronda et al., 2014; Sieverink, Kelders, et 
al., 2014)). In two studies, an initial high log-in frequency was observed that declined over time 
(Sieverink, Kelders, et al., 2014; Vugt et al., 2016). 
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Patients logged on to portals for various tasks. Of all the included studies, one study 
identified viewing laboratory results as the most frequently used feature, followed by requests for 
medication refills, sending and reading messages, and making appointments (Sarkar et al., 2011). 
Another study reported similar findings, with checking which laboratory tests were ordered by 
providers being the most frequent activity, followed by reading messages from providers and 
reviewing laboratory results (Tenforde et al., 2011). 
2.4.4  Patient characteristics of portal users and nonusers 
Significant differences between portal users and nonusers have been identified. Portal users 
were more likely to be younger (Ronda et al., 2013, 2014; Sarkar et al., 2011; Shimada et al., 2016; 
Tenforde et al., 2011; Weppner et al., 2010), white (Osborn et al., 2013; Sarkar et al., 2011; 
Shimada et al., 2016; Tenforde et al., 2011), and male (Ronda et al., 2013; Shimada et al., 2016; 
Weppner et al., 2010) with higher incomes (Osborn et al., 2013; Tenforde et al., 2011; Weppner 
et al., 2010) and greater educational attainment (Ronda et al., 2013, 2014; Sarkar et al., 2011; 
Tenforde et al., 2011). Other factors reported to be associated with portal use were higher health 
literacy (Sarkar et al., 2011) and higher morbidity (Weppner et al., 2010). Ronda et al found that 
insulin use, T1DM, longer duration of diabetes, polypharmacy, and treatment by an internist were 
associated with using the portal (Ronda et al., 2013, 2014, 2015) 
2.4.5  Impact of patient portals on glycemic control 
The impact of DM-specific patient portals on glycemic control was investigated in five 
RCTs. Of these, four targeted patients with T2DM and yielded inconsistent results. Tang et al 
randomized 415 patients to either the usual care group or the intervention group. The results 
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demonstrated reductions in HbA1c in the intervention group, where patients had access to a Web-
based diabetes management system, compared with that of the usual care group (−1.32% vs 
−0.66%, P<.001) at 6 months, but the difference between groups was no longer significant at 12 
months (−1.14 vs −0.95%, P=.13) (Tang et al., 2013). Ralston et al observed that the intervention 
group (n=42) in which patients were introduced to the Web-based diabetes support program had a 
greater decline in GHb than the usual care group (n=41) at 12 months (difference in mean change 
between groups=−0.7%, P=.01) (Ralston et al., 2009). Another two RCTs provided patients with 
access to portals in both groups. The only difference between groups in the study conducted by 
Grant et al. was the content of the module that was diabetes related in the intervention group but 
not the control group (Grant et al., 2008). In the study by Vugt et al, patients in the intervention 
group, but not in the control group, were able to request feedback from a health coach (Vugt et al., 
2016). Both these studies failed to observe changes in HbA1c over time in either group (Grant et 
al., 2008; Vugt et al., 2016). The study by McCarrier et al., which examined 77 patients with 
T1DM, did not find a significant decrease in the average HbA1c in the intervention group with a 
Web-based management program when compared with the usual care group over 12 months 
(McCarrier et al., 2009). 
 There were three observational studies that used data from EHR as well as an audit of portal 
registration and usage to examine the association of portal use with glycemic control. Of these 
three studies, two studies focused on single features (i.e., secure messaging, Web-based medication 
refill). The 5-year retrospective cohort study conducted by Shimada et al. in 111,686 veterans 
demonstrated that patients with HbA1c ≥7%at baseline tended to achieve HbA1c <7% with 2 (odds 
ratio [OR] 1.24, 95% CI 1.14 to 1.34) or more (OR 1.28, 95% CI 1.12 to 1.45) years of messaging 
use. Use of Web-based medication refills was not associated with changes in glycemic control 
(Shimada et al., 2016). An earlier study of 15,427 patients that examined the messaging feature 
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revealed that frequent use of messaging (i.e., ≥12 threads) was associated with HbA1c less than 
7% (relative risk [RR] 1.36, 95% CI 1.16 to 1.58) (Harris et al., 2009). Another study of 10,746 
adults, which investigated the association between overall portal use and diabetes quality 
measures, observed a minimum decrease in HbA1c was associated with an increase in portal use 
(0.02%, P<.01) (Tenforde et al., 2011). 
2.4.6  Impact of patient portals on other diabetes-related outcomes 
In addition to glycemic control, researchers also explored other diabetes-related 
physiological outcomes. The RCT by Tang et al. found that patients who had Web-based access 
to the diabetes management system had better control of LDL, but not BP or weight, when 
compared with patients in the usual care group at 12 months (P=.001) (Tang et al., 2013). A 
significant decline in LDL and BP was observed in two retrospective cohort studies that examined 
single features in the portal (Sarkar et al., 2014; Shimada et al., 2016). Sarkar et al. focused on 
individuals with diabetes who were prescribed statins. They observed that for patients with poor 
adherence to a statin medication at baseline (n=3887), those who requested all their medication 
refills on the Web during the 5-year study period had a 2.1 mg/dL decrease in LDL compared with 
nonusers (95%CI −4.4 to 0.18). This decrease in LDL can be explained by the improved statin 
adherence (Sarkar et al., 2014). Shimada et al. demonstrated that both secure messaging use and 
Web-based medication refill requests were associated with lower LDL at follow-up. Patients with 
uncontrolled BP at baseline tended to achieve better control at follow-up, if they used the Web-
based medication refill function for two (OR 1.07, 95% CI 1.01 to 1.13) or more years (OR 1.08, 
95% CI 1.02 to 1.14) (Shimada et al., 2016). Significant associations between portal use and 
improved physiological measures were reported by two other cross-sectional studies (Harris et al., 
2009; Tenforde et al., 2011). Tenforde et al. reported that portal users (n=4036), compared with 
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nonusers (n=6170), had a small difference in SBP (by 1.13 mm Hg, P<.01) and DBP (by 0.54 mm 
Hg, P<.01) (Tenforde et al., 2011). In the Harris et al. study of 15,427 patients, a small but 
significant association was observed between secure messaging use and LDL <100 mg/dL 
(P<.001) (Harris et al., 2009). Other studies did not find a difference in total cholesterol (Ralston 
et al., 2009; Vugt et al., 2016), LDL (Grant et al., 2008; Ralston et al., 2009; Tenforde et al., 2011), 
BP (Grant et al., 2008; Harris et al., 2009; Ralston et al., 2009; Tang et al., 2013; Vugt et al., 2016), 
or BMI (Vugt et al., 2016)between groups. 
 Several studies also assessed changes in psychological measures, including diabetes-
related distress and self-efficacy for managing diabetes. Data on diabetes-related distress as 
measured by the Problem Areas in Diabetes (PAID) questionnaire were reported in four studies. 
Of these studies, one study using an RCT design found a lower distress score in the intervention 
group (n=202) compared with the usual care group (n=213, 0.6, SD 0.8, vs 1.0, SD 1.0, P<.001) 
at 12 months (Tang et al., 2013). Self-efficacy between groups was assessed in two studies. In an 
RCT by McCarrier et al. (n=77 patients with T1DM), the intervention group had a significant 
increase in diabetes-related self-efficacy compared with the control group (P=.04) (McCarrier et 
al., 2009). The study from the Netherlands analyzed data from 1390 respondents and found a 
significantly higher self-efficacy score for portal users (i.e., patients with at least 1 log-in, 79.5, 
SD 15.8) than nonusers (i.e., patients without a log-in, 72.7, SD 17.8) among patients with T2DM 
(n=1262, P<.001) but not T1DM (n=128) (Ronda et al., 2013). 
2.4.7  Qualitative studies reporting benefits and barriers to using patient portals 
There were eight studies that evaluated patient portals by applying qualitative methods—
six used focus groups, one used face-to-face interviews, and one used telephone interviews. 
Qualitative responses revealed that patients favored features that allowed them to view summaries, 
 45 
request prescription refills, receive reminders for medical appointments, access laboratory results, 
and communicate with providers (Bryce et al., 2008; Hess et al., 2007; Osborn et al., 2013). 
Patients stated that benefits of using the portal included more awareness of their disease, increased 
access to care outside of office visits, enhanced communication and satisfaction, and promotion of 
behavior change (Hess et al., 2007; Urowitz et al., 2012; Wade-Vuturo et al., 2013). 
Patients who never used the portal provided the following reasons for not requesting a log-
in: unawareness of the existence of the portal, no use of computers, family members as delegates, 
slow response from physicians or nurses, and poor usability of the portal (Hess et al., 2007; Osborn 
et al., 2013; Urowitz et al., 2012). Mayberry et al. highlighted the role of family members in 
supporting patients’ access to and use of the portal, especially for those with limited health literacy, 
numeracy, or computer literacy. Family members taught the patient how to use each function in 
the portal, and some acted as delegates for patients by managing their health conditions (Mayberry 
et al., 2011). Several studies also identified that physician engagement in using the portal remains 
challenging. Providers with negative attitudes toward the portal listed lack of integration with work 
routine, minimal knowledge about the portal, limited time, and usability problems as reasons for 
not using the portal (Sieverink, Braakman-Jansen, et al., 2014; Urowitz et al., 2012). 
2.5 DISCUSSION 
2.5.1  Principal findings  
This literature review reported on the current evidence on EHR portal use in the clinical 
management of patients with diabetes. The 13 patient portals that were represented in the 30 studies 
showed wide variability in features examined and provided across portals, evaluated diabetes 
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outcomes, and whether the technology resources were applied in combination with a disease 
management program for diabetes. These variabilities increased the difficulty of performing a 
meta-analysis and generating any conclusions about the effectiveness of patient portals for diabetes 
management. In our review of the RCTs, we found inconsistent findings regarding the effect of 
the portal use on diabetes outcomes. Observational correlational studies also yielded mixed 
findings regarding the association between portal use and diabetes outcomes. However, we were 
able to identify that the patient portal, which leverages strong patient-centered principles (e.g., DM 
education, tailored feedback on patient’s DM-related health data), performed better in improving 
patient outcomes. The DM-specific portals enabled patients to receive personalized education, 
send blood glucose readings, and obtain individualized feedback from the health team. 
Although we observed more favorable outcomes associated with using the DM-specific 
portals, the effect sizes in the studies reviewed were small. This may be due to several challenges 
associated with the use of patient portals. The design of the majority of the patient portals currently 
available was not patient-centered, meaning that features provided do not align with patient 
expectations, and in many cases were not evidence based. For a self-management intervention to 
be effective, appropriate theories of engagement and implementation should be in place to support 
the evidence-based intervention. For example, to ensure the effective application of a system, the 
system needs to provide a complete feedback loop, which consists of multiple components that 
include monitoring and transmission of patient status, data interpretation in comparison with 
personalized goals, adjustment of treatment regimen based on patient status, timely 
communication with individualized recommendations, and repetitiveness of this cycle (Jimison et 
al., 2008). However, from the studies reviewed, current patient portals often provided only one of 
these functions or a subset of them, which may contribute to the less robust favorable results. To 
significantly improve diabetes management, patient portals need to do more than provide 
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convenient services such as requesting medication refills or reviewing laboratory results. They 
should also integrate more evidence-based strategies, such as patient education, to enhance patient 
engagement. 
The current state of low engagement by patients in portal use may interfere with the ability 
to achieve meaningful clinical benefits. Initial high log-in rates followed by a rapid decline in 
portal use suggest that multifaceted barriers prevented patients from engaging in the long-term use 
of patient portals. These barriers are technology-related (e.g., functionality, usability), patient-
related (e.g., access to the internet or a computer, low health literacy, perceived usefulness, 
sociodemographic and clinical characteristics), and provider-related (e.g., provider engagement). 
A recently published review indicated that endorsement from providers was one of the 
most influential factors that contributed to patients’ accepting the portal and using it as a tool for 
diabetes self-management (Irizarry et al., 2015). However, healthcare providers commonly 
expressed concerns toward using a patient portal such as a disruption of their workflow and time 
constraints. These challenges may limit physicians’ adoption and engagement of portal use and 
lead to minimal improvement in patient outcomes (Miller, Latulipe, Melius, Quandt, & Arcury, 
2016). Future research needs to focus on addressing these barriers to promote more physician 
involvement in using the portal. 
2.5.2  Limitations 
There were several noted limitations of this review. First, our findings lacked sufficient 
quality evidence; the results of this review are not well-supported by level A evidence, with the 
majority of studies graded as the B or C level. It is no longer feasible to randomly assign patients 
to either portal use or nonuse group as individuals have the right to access their health information, 
but studies could consider examining different designs or additional features, given the necessary 
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health information included in the portal. Second, this literature review only included studies 
explicitly concerned with patient portals and diabetes, studies evaluating patient portals for 
multiple chronic disease management that may include diabetes were not included. Finally, only 
one person was involved in the selection of the studies for inclusion in our review. Future studies 
should consider using a multiple-rater approach for study evaluation and data extraction. 
2.5.3  Conclusions  
In conclusion, this review identified several opportunities that could potentially improve 
diabetes outcomes through a patient portal. Because the majority of the studies examined the 
overall effect of patient portals, future investigations should consider investigating single features 
to understand the contribution of each component and understand which component is more 
influential than others in helping patients manage their diabetes. Moreover, a conceptual 
framework is needed to standardize an approach to guide the design and evaluation of patient 
portals. Specifically, functionalities need to be specified to provide guidance on system 
requirements for patient portal developers. Moreover, a set of evaluation metrics needs to be 
developed for the evaluation of patient portals to enable them to be compared and ranked. To 
further improve diabetes outcomes, continued investigation of strategies that could potentially 
enhance the implementation of the patient portal (e.g., portal design, implementation strategy) may 
enable the patient portal to reach its fullest potential in supporting diabetes management and 
increasing patient engagement. At the same time, physicians’ perceptions of portal use need to be 
assessed, and potential barriers need to be addressed to foster physicians’ engagement in patient 
portals. 
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3.0 MANUSCRIPT 2: USE OF A PATIENT PORTAL FOR ENGAGING PATIENTS 
WITH TYPE 2 DIABETES: PATTERNS AND PREDICTIONS 
3.1 ABSTRACT 
Objective: Patient portals empower patients by providing access to their health information 
and by facilitating communication with care providers. This study aimed to understand the usage 
patterns of a patient portal offered as part of an electronic health record (EHR) and to examine 
predictors of portal use among patients with type 2 diabetes (T2DM). Methods: A 2-year 
retrospective cohort study including patients who visited an outpatient setting of UPMC. 
Demographic and clinical data on 38,399 patients from the outpatient EHR were analyzed. 
Descriptive statistics were used to present portal usage patterns. Binary logistic regression was 
employed to examine predictors and two-way interactions associated with portal use. Results: 
Almost one-third of patients with T2DM (n=12,615; 32.9%, 95% CI: [32.38%, 33.32%]) had used 
the portal for an average of 2.5±1.9 years prior to the study. Portal use was higher on weekdays 
than weekends (p<0.001). An increase in portal use was observed in response to email reminders. 
A nonlinear relationship between age and portal use was observed, depending on several other 
predictors (ps<0.05). Patients living in more rural areas with low income, were less likely to use 
the portal (p=0.021), this finding also applied to non-whites with low income (p<0.001). More 
chronic conditions and a high HbA1c value were associated with patient portal use. Conclusions: 
Patient engagement in portal use can be facilitated through a proactive approach by healthcare 
providers. Additional research is needed to reduce disparities in portal use and to evaluate the 
effectiveness of portal use on diabetes outcomes. 
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3.2 INTRODUCTION 
The prevalence of type 2 diabetes (T2DM) has doubled in the past two decades (Selvin, 
Parrinello, Sacks, & Coresh, 2014), and the rate continues to rise at a significant rate (Rowley et 
al., 2017). Diabetes management remains challenging due to the growing number of adults with 
diabetes and the increasing complexity of self-management required by continuous adjustments in 
treatment. Engaging patients in self-management of their disease is essential to achieve adherence 
to treatment regimens that align with patient needs and preferences (Haas et al., 2012). Driven by 
the increasing use of health information technology, diabetes management greatly relies on 
facilitating patient access to health information and enhancing clinical decision support for more 
comprehensive and individualized care delivery during a clinical visit. 
Healthcare organizations frequently adopt patient portals to support patient access to health 
information with the goal of engaging patients in their care and self-management. A recent poll of 
1,756 healthcare leaders revealed that 90% of healthcare organizations offer a patient portal to 
patients (Medical Group Management Association, 2018). This particular type of personal health 
record (PHR) connects to a health organization’s electronic health record (EHR) system and 
provides patients with access to medical information including visit summary, medical history, 
medications, and lab results. Some advanced portals allow interactive functionalities such as 
scheduling appointments and facilitating communication with physicians. Patients are becoming 
increasingly interested in using these portals. It is anticipated that 75% of U.S. adults will adopt a 
patient portal by 2020 (Ford et al., 2016). 
Three earlier observational studies described patient portal use by patients with diabetes 
and noted that 27.8% - 37.6% of the patients used a portal (Sarkar et al., 2011; Tenforde et al., 
2011; Weppner et al., 2010). One study reported the following activities and proportion of patients 
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who performed them in their use of the portal: 53% viewed lab results, 28% requested medication 
refills and 15% scheduled appointments (Sarkar et al., 2011). All studies examined portal usage 
before 2009 when the Meaningful Use (MU) incentive program was enacted. The MU program 
provided physicians with monetary incentives for allowing patients to access their health 
information and communicating with patients on health issues. To date, few recent studies that 
have examined the usage of an EHR based patient portal following implementation of this 
incentive program. 
With the increasing attention on patient portals and the expectation to improve patient 
outcomes, it is critical to understand when patients use the portal, which patients use the portal, 
and what features patients use when accessing the portal. The aims of this study were to: 1) 
describe the usage pattern of the patient portal in patients with T2DM over time, including what 
features the patients accessed and when patients used the portal (i.e., weekdays vs. weekend, 
proximity to a face-to-face clinic visit), and 2) examine the associations of patient demographics 
(e.g., age, gender, race) and clinical characteristics (e.g., number of chronic conditions, initial 
HbA1c value, insulin use, number of primary care physician visits) with portal use.  
3.3 METHODS 
3.3.1  Study Design 
This study employed a 2-year retrospective, longitudinal cohort design using existing data 
from the ambulatory EHR of University of Pittsburgh Medical Center (UPMC) Physician Services 
(Epic Systems, Verona, WI). The study was approved by the University of Pittsburgh Institutional 
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Review Board (IRB), and an honest broker system was used to obtain the de-identified protected 
health information. 
3.3.2  Setting and Patient Selection 
UPMC has over 600 doctors’ offices and outpatient sites throughout western Pennsylvania. 
The cohort of patients with T2DM was identified using the International Classification of Diseases, 
Ninth Revision (ICD-9) diagnosis codes of 250.* and the International Classification of Diseases, 
10th Revision (ICD-10) diagnosis codes of E11.* Patients were included if they were prescribed 
diabetes medications and had HbA1c results posted during the study period. Our use of two or 
more indicators have previously demonstrated accuracy to determine whether or not patients have 
diabetes (Zgibor et al., 2007). Potential patients with type 1 diabetes were removed from the 
analysis as indicated by having only ICD-9 code for type 1 diabetes without ICD-9 code for type 
2 diabetes, or age being younger than 40 years who were prescribed only insulin (Lo-Ciganic et 
al., 2011). Patients were further excluded if they 1) were newly diagnosed with T2DM, 2) had only 
one specialty care visit, and 3) were new to the portal during the study period. As a result, a total 
of 38,399 patients were included in the study. Figure 2 presents the cohort selection process for 
this study. 
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Figure 2. Cohort Selection Diagram 
Identify Patients with DM 
1) having HbA1c results & 
2) diabetes medications 
（n=63,071） Excluded patients (n=1,581) with 
T1DM 
1) having ICD-9 code of T1DM (250. 
x1 or 250.x3) without ICD code of 
T2DM; or  
2) Age<40 years & prescribed only 
insulin   
Patients with T2DM included in the 
cohort  
(n=61,490) 
Patients who have diabetes code either 
ICD-9 250.* or 
ICD-10 E11.* between years of 2015 
and 2016 
(N=98,382) 
Patients included in the study  
(n=38,399)  
Excluded patients (n=23,091) with  
1) newly noted diabetes during the 
study period;  
2) only 1 specialty care visit; or  
3) new to the portal  
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3.3.3  Measures 
3.3.3.1 Demographic and Socioeconomic Characteristics 
Patient demographic data extracted from the EHR included age, gender, race, primary 
health insurance, and zip code. We linked neighborhood summary statistics from the U.S. Census 
Bureau’s 2011-2015 American Community Survey (5-year estimate) to each patient via their 5-
digit zip code (US Census Bureau, 2015). The patient socioeconomic characteristics that were 
estimated from U.S. Census data included educational attainment, urbanization, and median 
household income for the particular zip code. Education attainment was a continuous variable 
defined as the proportion of residents who had obtained a bachelor’s degree or higher in a specific 
zip code. Urbanization was measured as the proportion of residents within an urbanized area in a 
specific zip code. 
3.3.3.2 Clinical Characteristics 
Table 3 summarizes the data retrieved from the EHR and the variables to be considered as 
predictor variables in the modeling. The laboratory test results contained the date of the HbA1c 
test and the value of HbA1c result. We calculated the total number of HbA1c tests that were 
performed for each patient over the study period and included the first reported HbA1c value for 
each patient in the analysis. 
Patient-prescribed medications were retrieved from the medication prescriptions. Insulin 
use and the glucose-lowering medications for T2DM were identified using the therapeutic classes 
according to the American Hospital Formulary Services (AHFS) Pharmacologic-Therapeutic 
Classification System (American Society of Health-System Pharmacists, 2016). The number of 
different diabetes medications prescribed to each patient was determined. Insulin use was a binary 
variable (yes/no) representing whether or not the patient was prescribed insulin. 
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Table 3. Variables Represented in the Electronic Health Record and in the Model 
Data category  Representation in EHR Represented in model as  
Administration Age, gender, race, primary 
health insurance 
Age, gender, race, health insurance 
(Medicare, Medicaid, Commercial, 
Self-insured, Other) 
Laboratory 
results  
Date of HbA1c test and result Initial HbA1c result, total # of 
HbA1c tests 
Medication 
orders 
Name and date of prescribed 
medications 
Insulin use (yes/no), total # of distinct 
diabetes medications 
Visits  Type of visit and visit date Total # of PCP visits 
Encounter 
diagnosis  
ICD diagnosis code Total # of distinct chronic conditions 
Telephone 
contact 
Contact date Total # of telephone contacts 
 
Patient comorbidities were calculated using the chronic disease indicator that was found in 
the Clinical Classification System (CCS) developed as part of the Healthcare Cost and Utilization 
Project (HCUP) sponsored by the Agency for Healthcare Research and Quality (AHRQ) (Agency 
for Healthcare Research and Quality, 2016). The CCS determines whether an ICD code represents 
a chronic or non-chronic condition. The total number of comorbidities for each patient was 
calculated by summing the distinct clinical problems of each patient. 
Healthcare utilization data obtained included primary care physician (PCP) visits and 
telephone contacts. We calculated the total number of visits to a PCP office and the total number 
of telephone contacts with healthcare providers during the 2-year study period for each patient. 
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3.3.4  Statistical Analysis 
Analyses were performed in R Statistical Software (R version 3.5.1 and R Studio 1.1.456). 
Using summary statistics, we characterized patients regarding their demographic and clinical 
characteristics overall and by portal use (yes/no). Medians and interquartile ranges (IQR) were 
reported for the continuous variables with skewed distributions, and frequencies and percentages 
were reported for categorical variables. Comparisons of patient characteristics between portal 
users and non-users were performed using either Mann-Whitney U-tests or Chi-square tests of 
independence as appropriate. 
The portal features that the patient used were categorized into six major types: manage 
appointments, view medical summaries, update and share medical information, renew medication 
prescriptions, view lab results, and access messages. To describe patient portal usage around a 
clinic visit, we used each patient’s first visit as an example and created two-week windows before 
and after the day of visit. For each day within the window, we indicated whether or not the patient 
used the portal. A line chart was plotted to describe the number of users of each day within the 
window. Furthermore, we calculated the total number of access events to each portal feature 
category Monday through Sunday to describe the usage patterns by the day of the week. 
Comparison of the average daily portal usage between weekdays and weekends was performed 
using the Wilcoxon signed-rank test for two-related samples. A line chart was used to present the 
portal usage by the day of the week.  
Binary logistic regression was used to investigate the association between patient 
characteristics and the probability of the use of the patient portal (use vs. non-use). Test statistics, 
including p-values, adjusted odds ratios (OR), and their corresponding 95% confidence intervals 
(CI) for each predictor variable were reported. Missing data on certain zip codes were found in the 
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three variables linked from the U.S. Census Bureau including education attainment (n = 115), 
urbanization (n = 112), and household income (n = 192). Also, a small number of patients (n = 24) 
had missing values on initial HbA1c due to either problematic entries or implausible values (i.e., 
HbA1c < 3.5%, HbA1c > 20%). The percentage of patients with missing data (n = 216) was less 
than 1% of the total sample. A comparison of patient demographics between those with missing 
and without missing was performed, and showed that patients with missing resided in areas with 
a slightly lower percentage of people with bachelor or higher degree (median 17.9%) as compared 
to those with complete data (median 24.8%); however, the small difference may not have practical 
meanings. Thus, listwise deletion was applied to remove cases with missing values. Due to the 
relatively small number of cases in certain categories of race and insurance, we collapsed race 
categories “Black” and “Other (Asian, American Indian, Alaska Native, Other Pacific Islander, 
and not specified)” into “Other”. Insurance categories “Medicaid”, “Self-insured”, and “Other 
(Auto, VA Health Care, and Worker Compensation)” were grouped together as “Other”. Predictor 
variables with a p-value of less than 0.20 in the bivariate analyses were included in the binary 
logistic regression analysis with multiple explanatory covariates. The linearity assumption of 
continuous independent variables with the logit of the probability of portal use was checked using 
the Box-Tidwell test; the results showed that age and education were non-linearly related with the 
logit of the probability of portal use. We further categorized age and education into four categories 
and re-ran the model and plotted the log odds ratios for each category against the mid-point values 
of each category to determine the appropriate scaling of age and education as age squared and log 
base 10 (education + 1) in the multivariable model because they demonstrated the smallest Akaike 
information criterion (AIC) when compared to other forms of transformation. Two-way 
interactions between the predictor variables were also assessed. We performed mean centering of 
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the age variable in the model due to its high multicollinearity with insurance. The Cook’s distance 
was calculated, and no potential influential data point was identified. 
We split our dataset into two parts, using the dataset containing 75% of the sample for 
model training and the remaining 25% of the sample for model testing. Using the training dataset, 
a manual backward elimination procedure was used to remove non-significant variables (p < 0.05) 
to generate a parsimonious model. The Hosmer-Lemeshow (H-L) test were applied to assess the 
model fit. Using the model obtained from the training dataset, we evaluate evaluation was 
performed in the testing dataset by calculating the model sensitivity and specificity. A receiver 
operating characteristic (ROC) curve was plotted to identify the optimal threshold value, and the 
percentage of the area under the ROC curve (AUC) was determined to indicate the model 
discrimination; a percentage of 70% or higher is considered high discrimination between portal 
users and non-users (Rice & Harris, 2005). 
3.4 RESULTS 
The sample (N= 38,399) was primarily white (85.2%) with a mean age of 63.49 (SD 11.89) 
years. Slightly over half of the patients (54.10%) were insured by Medicare. The neighborhood-
estimated variables linked from the Census Bureau showed that patients resided in areas, where 
on average 28.69% (SD 14.15%) had at least a bachelor’s degree, and 80% (SD 30.29%) were 
urbanized areas, with a median household income of $51,054 (SD $16,595). The mean number of 
HbA1c tests that patients had performed was 2.93 (SD 1.38) with an average initial HbA1c (%) 
value of 7.63 (SD 1.67). Additionally, our sample of patients with T2DM had on average 7.31 (SD 
3.77) chronic conditions, were prescribed on average 1.78 (SD 1.0) distinct diabetes medications, 
and 37.3% were prescribed insulin. The average number of telephone contacts documented with 
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healthcare providers was 14.2 (SD 15.3) with an average 7.67 (SD 6.40) primary care physician 
visits during the 2-year study period.  
3.4.1  Patient Portal Usage 
Nearly one-third (n = 12,615, 32.9%, 95% CI: [32.38, 33.32]) of the sample used the portal 
for a median of 31 days with interquartile range (IQR) of 44 days between January 2015 and 
December 2016. Among the 12,615 portal users, patients with T2DM had used the portal for an 
average of 2.48 years (SD 1.91) prior to the beginning of the study. Table 4 presents detailed 
information on the number of users for each portal feature category by the frequency of access 
(i.e., 1~9 times, 10-19 times, and ≥ 20 times). The most frequent feature accessed by these portal 
users was viewing medical summaries (38.4%), followed by viewing lab results (25.2%), using 
secure messaging (13.7%), managing appointments (11.3%), updating and sharing medical 
information (8.6%), and renewing medication prescriptions (2.9%). 
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Table 4. Description of portal features accessed by portal users with T2DM (n=12,615) from 2015 to 2016 
Category Activity description # users 
(%) 
# users (%) 
accessed 
1~9 times 
# users (%) 
accessed 
10-19 
times 
# users 
(%) 
accessed  
≥ 20 
times 
View lab 
results  
Lab tests ordered 
Lab results 
Results component 
graphing  
12,359 
(98.0%) 
1,906 
(15.1%) 
2,150  
(17.0%) 
8,303 
(65.8%) 
View 
medical 
summary  
Allergies 
Medications 
Immunizations 
Health snapshot 
Health maintenance 
Problem list 
My conditions 
Visit summary  
Histories 
Encounter details 
12,265 
(97.2%) 
1,391 
(11.0%) 
1,596  
(12.7%) 
9,278  
(73.5%) 
Electronic 
messaging 
Messaging  12,170 
(96.5%) 
3,990 
(31.6%) 
2,923 
(23.2%) 
5,257 
(41.7%) 
Manage 
appointment  
Appointment review  
Appointment details  
Appointment schedule 
Appointment auto-
schedule 
Appointment confirmation 
Appointment cancel 
11,681 
(92.6%) 
4,921 
(39.0%) 
2,807 
(22.3%) 
3,953 
(31.3%) 
Update and 
share 
medical 
information  
Update medications  
Update allergies 
Patient-initiate 
questionnaires  
Patient entered flowsheet 
Flowsheet reports list 
Flowsheet report details  
History questionnaire  
Questionnaire  
11,341  
(89.9%) 
5184 
(41.1%) 
2,931  
(23.2%) 
3,226  
(25.6%) 
Renew 
prescription 
Medication renewal 
request 
9,351 
(74.1%) 
7,325 
(58.1%) 
1,402 
(11.1%) 
624  
(4.9%) 
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Figure 3. Portal Access Between January 2015 and December 2016 by Feature Category 
 
Overall, the usage of each portal feature remained relatively stable from January 2015 to 
July 2016 (Figure 3). Noticeable changes in portal usage occurred on August 2016 due to a system 
upgrade; numerous functionalities had been modified with that release, which could have changed 
their login to the portal. We observed that the patient usage patterns differed by the day of the 
week. Patients tended to access the portal on weekdays rather than during weekends (median 
(IQR): 28.00 (37) vs. 17.50 (25), p < 0.001). More frequent access occurred at the beginning of 
the week and toward the end of the week, except for the messaging feature where a consistent high 
usage was observed from Monday through Friday (Figure 4). Moreover, we noted that patients 
were more likely to use the portal prior and after a clinic visit (Figure 5), and a reminder email 
before an office visit facilitated portal access of patients. 
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Figure 4. Number of Portal Accesses by Feature and Day of the Week 
 
Figure 5. Daily Number of Portal Users Two Weeks Before and After the First Clinical Visit in the Two-year 
Period 
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3.4.2  Portal Users versus Non-users 
Table 5 summarizes the patient demographic and clinical characteristics of the overall 
sample and the results for the bivariate analysis of variables between portal users and non-users. 
Compared to non-users, portal users tended to be younger (p < 0.001); be male (p = 0.001); resized 
in zip codes that have higher median household income (p < 0.001), higher education level (p < 
0.001), and higher percent of urbanization (p < 0.001); were prescribed more distinct glucose-
lowering drugs (p < 0.001); and had a greater number of chronic conditions (p = 0.001). Also, we 
noted a significantly greater number of HbA1c tests performed (p < 0.001) and a lower median 
initial HbA1c value (p < 0.001) among portal users than non-users. Regarding healthcare 
utilization, portal users were less likely to use alternative forms of care delivery methods such as 
telephoning (p < 0.001) or visiting a primary care physician (p < 0.001) during the study period. 
No difference in insulin use was observed between portal users and non-users (p = 0.114). 
 
 
 
 
 
 
 
 
 
 
 
 
 64 
Table 5. Characteristics of Study Patients with T2DM and by Portal Use Groups 
Demographics 
Overall 
(n=38,399) 
Median (IQR)/ 
n (%) 
Portal user 
(n=12,615) 
Median (IQR)/ 
n (%) 
Portal non-user 
(n=25,784) 
Median (IQR)/ 
n (%) 
p-value 
Age, years 64.00 (16) 62.00 (14) 66.00 (17) <0.001 
Gender     0.001 
Female 19,140 (49.9%) 6,129 (48.6%) 13,011 (50.5%)  
Male 19,259 (50.1%) 6,486 (51.4%) 12,773 (49.5%)  
Race     <0.001 
White 32,706 (85.2%) 11,339 (89.9%) 21,367 (82.9%)  
Black 4,895 (12.7%) 935 (7.4%) 3,960 (15.4%)  
Other 798 (2.1%) 341 (2.7%) 457 (1.8%)  
Household income, 
Median 
$48750  
($16,227) 
$52,128 
($19,852) 
$47,216 
($14,235) 
<0.001 
Bachelor’s degree and 
above, %  
24.80 (19.3) 28.80 (21.2) 23.20 (17.5) <0.001 
Urbanization, %  95.64 (30.9) 96.73 (23.6) 94.73 (33.1) <0.001 
Insurance type    <0.001 
Medicare 20,772 (54.10%) 5,542 (43.93%) 15,230 
(59.07%) 
 
Commercial 13,773(35.87%) 6,119 (48.51%) 7,654 (29.69%)  
Medicaid 2,671 (7.00%) 548 (4.34%) 2,123 (8.23%)  
Self-insured 1,048 (2.73%) 345 (2.73%) 703 (2.73%)  
Other 135 (0.35%) 61 (0.05%) 74 (0.03%)  
# of distinct glucose-
lowering drugs 1.00 (1) 2.00 (1) 1.00 (1) <0.001 
Insulin use    0.114 
Yes 14,324 (37.3%) 4,635 (36.7%) 9,689 (37.6%)  
No 24,075 (62.7%) 7,980 (63.3%) 16,095 (62.4%)  
Initial HbA1c value 7.10 (1.70) 7.10 (1.60) 7.10 (1.70) <0.001 
# of HbA1c tests 3.00 (2) 3.00 (2) 3.00 (2) <0.001 
# of chronic conditions 6.00 (4) 7.00 (4) 6.00 (4) 0.001 
# of telephone contacts 9.00 (14) 9.00 (13) 10.00 (14) <0.001 
# of primary care 
physician visits  7.00 (6) 6.00 (5) 7.00 (6) <0.001 
Note. Comparisons between groups were conducted using Mann-Whitney U test or Chi-
Square test of independence where appropriate. 
 
Results of binary logistic regression analysis including multiple explanatory variables and 
significant two-way interactions are presented in Table 6. In general, the effects of age, race, 
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income, and the number of chronic conditions on portal usage were modified by several other 
predictors. A non-linear relation between age and portal usage was found to be dependent on eight 
other predictors in the model including one’s race, household income education attainment, 
number of telephone contacts, initial HbA1c value, use of insulin, and the number of prescribed 
glucose-lowering drugs (ps < 0.05). Those who were white (linear OR = 0.98859, 95% CI: 
[0.97939, 0.99788]), had a higher education (linear: OR = 1.00753, 95% CI: [1.00183, 1.01327]), 
and a lower initial HbA1c (linear: OR = 0.99801, 95% CI: [0.99622, 0.99981]) were more likely 
to be a portal user particularly among older people. Females were more likely to use the portal 
compared to males among patients younger than 65 years, and males were more likely to be portal 
users among those older than 65years (linear: OR = 1.03900, 95% CI: [1.03316, 1.04487], 
quadratic: OR = 1.00075, 95% CI: [1.00043, 1.00107]). 
Table 6. Binary Logistic Regression for Predictors of Patient Portal Use 
Characteristic  p-value 
Adjusted 
Odds Ratio 
(OR) 
95% CI for OR 
Lower limit Upper limit  
Main effects     
Age (centered) < 0.001*** 0.93865 0.91700 0.96080 
Age2 (centered) < 0.001*** 0.99655 0.99606 0.99705 
Gender     
Female Reference    
Male < 0.001*** 0.87918 0.82105 0.94144 
Race     
White Reference    
Non-White < 0.001*** 0.23060 0.15899 0.33446 
Household income < 0.001*** 1.00005 1.00003 1.00007 
Education, log10[Education+1] < 0.001*** 1.96705 1.62987 2.37399 
Urbanization  0.196 1.00481 0.99753 1.01215 
Insurance      
Medicare Reference    
Commercial < 0.001*** 1.29292 1.19383 1.40023 
Other < 0.001*** 0.66744 0.57291 0.77757 
# of distinct glucose-lowering 
medications 0.135 0.96989 0.93174 1.00959 
Insulin use      
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Non-use Reference    
Use 0.927 1.00643 0.87784 1.15386 
Initial HbA1c value < 0.001*** 0.85054 0.77732 0.93065 
# of chronic conditions 0.763 1.00582 0.96862 1.04445 
# of telephone contacts < 0.001*** 0.85054 0.77732 0.93065 
# of HbA1c tests 0.786 0.98990 0.92012 1.06497 
# of PCP visits  < 0.001*** 0.98849 0.98326 0.99375 
Interaction effects      
Age ´ Gender     
Age ´ Female Reference    
Age ´ Male < 0.001*** 1.03900 1.03316 1.04487 
Age ´ Race     
Age ´ White Reference    
Age ´ Non-white 0.016 0.98859 0.97939 0.99788 
Age ´ Insurance     
Age ´ Medicare Reference    
Age ´ Commercial < 0.001*** 0.97849 0.97080 0.98624 
Age ´ Other 0.118 1.01238 0.99687 1.02813 
Age ´ Education 0.009** 1.00753 1.00183 1.01327 
Age ´ # of telephone contacts 0.033* 1.00021 1.00002 1.00041 
Age ´ Initial HbA1c value 0.030* 0.99801 0.99622 0.99981 
Age ´ Insulin use     
Age ´ Insulin non-use Reference     
Age ´ Insulin use 0.049* 0.99382 0.98770 0.99997 
Age ´ # of distinct glucose-
lowering medications 0.395 1.00135 0.99824 1.00447 
Age2 ´ Gender     
Age2 ´ Female Reference     
Age2 ´ Male < 0.001*** 1.00075 1.00043 1.00107 
Age2 ´ Insurance      
Age2 ´ Medicare Reference    
Age2 ´ Commercial < 0.001*** 1.00117 1.00074 1.00160 
Age2 ´ Other < 0.001*** 1.00251 1.00192 1.00310 
Age2 ´ # of telephone contacts < 0.001*** 1.00003 1.00001 1.00004 
Age2 ´ # of distinct glucose-
lowering medications 0.036* 1.00018 1.00001 1.00034 
Race ´ Insurance     
Race ´ Medicare Reference    
Race ´ Commercial 0.043* 1.25582 1.00765 1.56512 
Race ´ Other 0.015* 0.68782 0.50803 0.93123 
Race ´ Income     
White ´ Income Reference     
Non-White ´ Income < 0.001*** 1.00001 1.00001 1.00002 
Race ´ # of HbA1c tests     
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White ´ # of HbA1c tests Reference    
Non-White ´ # of HbA1c 
tests 0.007** 1.09895 1.02642 1.17660 
Urbanization ´ Household 
Income  0.021* 0.9999999 0.9999998 1.0000000 
Urbanization ´ Initial HbA1c 0.030* 1.00071 1.00007 1.00136 
Education ´ Household Income 0.003 ** 0.999994 0.999990 0.999998 
Household Income ´ # of 
HbA1c tests 0.002 ** 1.000002 1.000001 1.000003 
Household Income ´ Initial 
HbA1c value 0.021* 0.999999 0.999998 1.000000 
# of telephone contacts ´ # of 
chronic conditions 0.042* 1.00033 1.00001 1.00064 
Initial HbA1c value ´ # of 
chronic conditions 0.014* 1.00606 1.00120 1.01094 
Insulin use ´ # of glucose-
lowering medications     
Insulin non-use ´ # of 
glucose-lowering 
medications Reference     
Insulin use ´ # of glucose-
lowering medications 0.038* 1.06549 1.00353 1.13128 
 
Household income appeared to be an important predictor of portal use. Patients with a 
higher income who had performed more HbA1c tests (OR = 1.000002, 95% CI: [1.000001, 
1.000003]) or had a low initial HbA1c value (OR = 0.999999, 95% CI: [0.999998, 1.000000]) 
were more likely to use the portal. Importantly, we found that patients with a low household 
income living in a rural area were less likely to use the portal, except for those with a high 
household income (OR = 0.9999999, 95% CI: [0.9999998, 1.00000]). The association of 
household income and portal usage also depended on one’s race. Both whites and non-whites with 
higher incomes had a higher probability of being a portal user. Whites with incomes less than 
$110,000 were more likely to use the portal than non-whites and non-whites were more likely to 
use the portal when their household income was over $110,000 (OR = 1.00001, 95% CI: [1.00001, 
1.00002]).  
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Patients who had a greater number of chronic conditions with a high initial HbA1c value 
(OR = 1.00606, 95% CI: [1.00120, 1.01094]) or with fewer telephone contacts (OR = 1.00033, 
95% CI: [1.00001, 1.00064]) tended to use the portal. The number of PCP visits was also found to 
be independently associated with portal use after controlling for other predictor variables in the 
model. Portal users tended to have fewer PCP visits (OR = 0.988, 95% CI: [0.983, 0.993]). Lastly, 
we found that portal users had a smaller number of telephone contacts in the middle and older age 
groups (> 40 years old), but not in the young adult group (< 40 years old) (linear: OR = 1.00021, 
95% CI: [1.00002, 1.00041]; quadratic: OR = 1.00003, 95% CI: [1.00001, 1.00004]).  
The H-L test yielded a significant result (c2 = 11.081, p = 0.197), showing the model fit 
the training data very well. Additionally, model performance was evaluated on the testing dataset. 
A sensitivity of 76.7% and a specificity of 51.0% were yielded with a threshold value set at 0.4. 
The percentage of the area under the curve was 71.1%, indicating high discrimination between the 
portal users and non-users.  
3.5 DISCUSSION 
Our study examined the actual use of patient portal functions offered as part of an EHR by 
a large healthcare organization. One-third (32.9%) of the patients with T2DM had accessed the 
portal between January 2015 and December 2016. This number is slightly higher than what has 
been reported recently by the Office of the National Coordinator for Health Information 
Technology (ONC), where it was reported that 28% of patients viewed the online medical record 
at least once within the past year (Patel & Johnson, 2018). Among portal users, we observed a 
sustained use of the portal over the two-year study period, and 70% of patients logged in to view 
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medical summary information more than 20 times, suggesting that patients with T2DM engaged 
in using the portal and that the portal was convenient for reviewing medical information.  
We identified times when patients were more likely to use the portal. Patients were more 
likely to use the portal on weekdays than on weekends. This weekly usage pattern was consistent 
with internet usage by the day of the week, where Monday has the highest usage rates and 
weekends have the lowest rates (Mozilla, n.d.). Additionally, although the portal is available 24/7, 
patients tended to interact with the portal as a reaction to an email about updates in the portal. An 
upcoming visit facilitated patients’ logging into the portal to confirm their appointment and 
complete health history forms; after a visit, patients logged into the portal to check lab results. 
These observed usage patterns suggest that healthcare providers could take advantage of the usage 
pattern to proactively engage patients in performing self-care activities. For example, a reminder 
email of prescription renewal sent to patients may help facilitate timely medication refill and 
improve medication adherence.  
Our results expand upon prior research showing that portal use was related to certain 
demographic characteristics, including being white, having attained a higher level of education, 
higher household income, and having commercial health insurance (Jhamb et al., 2015; Perzynski 
et al., 2017; Tenforde et al., 2011). We found a parabolic association between age and portal use. 
Patients in young and middle-aged groups demonstrated an increase in portal use as they aged. 
While in older adults, increased age was associated with being less likely to use the portal. This 
finding can be explained by the gradually developed health issues among young and middle-aged 
adults that may require greater use of healthcare services. Older adults aged 65 or older, when 
compared to people in their 50s and early 60s, were less likely to use the computer for 
communication about their health issues or were not comfortable with technology (Malani, 2018). 
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Additionally, a consistent finding was that differences exist in access to and use of personal 
health information between residents of rural and urban areas. Patients who live in a rural area, 
where access to the internet might be limited, are less likely to use the portal compared to patients 
who live in an urban area (Greenberg, Haney, Blake, Moser, & Hesse, 2018). Our study expands 
on this result that portal use was not a concern for rural dwellers with a relatively high household 
income. Moreover, we observed that portal users, despite having greater number of chronic 
conditions, had a smaller number of PCP visits and telephone contacts, which may indicate that 
the portal can assist with addressing some questions patients have about their health and may 
replace the need for a physician or clinic visit or phone conversation.  
Although we found sustained use of the portal in our sample of patients with T2DM who 
used the portal, two-thirds of the patients with T2DM have not yet adopted the patient portal. There 
persists a digital divide in access to and use of such technology. This disparity in the use of patient 
portal and emerging health information technology may negatively affect the existing health 
disparities in diabetes outcomes. Strategies need to be identified to reduce these discrepancies. 
Patient education and development of skills in using technology are important since patients may 
not be aware of the portal or not perceive the value of portal use (Osborn et al., 2013; Ronda et al., 
2014). Strategies and avenues are needed to help patients understand the benefits of using the 
patient portal. Finally, smartphone ownership has almost become universal (Pew Research Center, 
2018). In the United States, low-income adults in particular, are increasingly accessing the internet 
only via mobile devices (Horrigan, Rainie, & Page, 2015). As consumers make a shift away from 
traditional desktop computers to more mobile options, patient portals need to be available in a 
more convenient form to allow easy and quick access. 
Our study has several strengths and limitations. It assesses the real-world use of a patient 
portal as part of a large healthcare organization serving patients with T2DM. Sufficient data were 
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available to reveal detailed usage patterns, and linear and non-linear associations between patient 
characteristics and portal use were examined with two-way interactions. Several limitations also 
need to be acknowledged. Our results are based on an analysis of data from a single healthcare 
organization, which may not generalize to other medical centers that offer patient portals with 
different functionalities, or on a different platform. Additionally, the large sample of the study 
provided sufficient power to detect small differences in patient characteristics between portal users 
and non-users; however, these small odds ratios observed may lack practical relevance and were 
unlikely to be clinically meaningful. Last, the neighborhood-estimated variables from the U.S. 
Census were linked via each patient’s zip code that may span a wide range of areas and cover a 
significant variation in socioeconomic status.  
In conclusion, portal users in our sample of patients with T2DM demonstrated continued 
usage of the portal over time; email reminders significantly facilitated patient access to the portal. 
Healthcare providers may consider proactive approaches to reach patients through the portal and 
engage them in managing their chronic conditions. Ultimately, the impact of patient portals will 
rely on the portal’s ability to reach across populations and have an impact on self-care and 
outcomes. Discrepancies in technology use could lead to a healthcare divide if issues remain 
unaddressed. Future research needs to examine the barriers to portal use in underserved 
populations with T2DM and engage patients who have not adopted the portal but could benefit the 
most from using it. Future research also needs to evaluate the effect of portal use on diabetes 
outcomes.  
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4.0 MANUSCRIPT 3: A LONGITUDINAL EXAMINATION OF PATIENT PORTAL 
USE ON GLYCEMIC CONTROL AMONG PATIENTS WITH TYPE 2 
DIABETES 
4.1 ABSTRACT 
Background: Optimal glycemic management reduces complications and promotes quality 
of life in patients with type 2 diabetes mellitus (T2DM), yet achieving this goal remains a 
challenge. Activating patients and enhancing care delivery using a patient-centered approach are 
essential for improving glycemic control. Patient portals hold the potential to address these 
challenges and provide ongoing care for the growing population with diabetes. Objective: Prior 
research has demonstrated inconsistent results on the association between patient portal use and 
glycemic control. Also, these studies are limited by their cross-sectional design. Our study 
longitudinally examined changes of HbA1c over time between users and non-users of a patient 
portal in individuals with uncontrolled T2DM. Methods: This study employed a retrospective 
cohort design using existing data over a 2-year period from an electronic health record (EHR) and 
its ancillary patient portal. Patients with T2DM who visited an outpatient setting of the University 
of Pittsburgh Medical Center (UPMC) from January 2015 to December 2016 were included if they 
had 1) initial HbA1c value greater than 7%, and 2) two or more HbA1c assessments during the 
study period. Propensity score matching (PSM) technique was used to balance the portal user and 
non-user group on demographic and clinical covariates. Linear mixed-effects modeling was 
employed to investigate the impact of the portal on patient HbA1c over time. Results: The patient 
cohort (N=15,528) was 85.9% white and 52.5% female. On average, patients were 62.8±11.7 years 
of age with a BMI of 34.2±7.2 kg/m2 and an initial HbA1c of 8.5±1.5%. Before PSM, patients who 
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used the portal were more likely to be younger, white, have higher education and income, 
commercially insured and live in an urbanized area (all p<.001). Moreover, portal users tended to 
have a higher BMI (p<.001), a lower initial HbA1c (p<.001), more frequent HbA1c assessments 
(p=.001), a greater number of medications for diabetes (p<.001), and visit an endocrinologist 
(p<.001). After PSM, both portal user (n=4,924) and non-user (n=4,924) groups were balanced on 
these demographic and clinical characteristics except for health insurance. Linear mixed-effects 
regression modeling showed a nonlinear decrease for HbA1c in both groups over time. A 
significant interaction was observed, with a greater decline and less rise of HbA1c in the portal 
users than the non-users. Conclusions: These findings support patient portals as promising tools 
for improving clinical outcomes in patients with T2DM. Healthcare providers need to consider 
strategies to encourage patients to adopt and use the portal for managing their chronic conditions. 
Future research is needed to examine the mechanisms through which portal use contributes to 
better outcomes.  
4.2 INTRODUCTION 
Type 2 diabetes (T2DM) is a significant public health concern that affects 30.2 million 
adults in 2015 in the United States (US) (Centers for Disease Control and Prevention, 2017a). 
Optimal glycemic management effectively minimizes the complications and improves quality of 
life (Khaw et al., 2001; Stratton et al., 2000); however, nearly 50% of patients do not achieve 
desired levels of  glycemic control as measured by hemoglobin A1c (HbA1c) of <7% (Carls et al., 
2017; Menon & Ahluwalia, 2015). 
Diabetes imposes a substantial financial burden on the US healthcare system; in 2017, 
every 1 in 4 healthcare dollars were spent on caring for individuals with diabetes (American 
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Diabetes Association, 2018). At the same time, the demand for providing ongoing health care for 
the increasing number of people with diabetes is one of the most significant challenges in the 
coming decades. Innovative approaches that enable continuous care for this rapidly increasing 
population are greatly needed.  
The Chronic Care Model (CCM) provides an evidence-based framework that enhances 
care delivery by modifying essential components of the healthcare system to support patient-
centered care for chronic disease (E. Wagner, 1998). The key elements of the CCM include health 
systems, decision support, clinical information system, patient self-management support, 
community resources, and delivery system design (Improving Chronic Illness Care (ICIC), 2015). 
The American Diabetes Association emphasized that diabetes care needs to be consistent with the 
elements of the CCM to ensure productive interactions between a prepared practice team and an 
informed patient (American Diabetes Association, 2015). The CCM has been widely used to 
improve the management of diabetes, and it has been shown to be an effective framework for 
increasing the quality of diabetes care (Coleman, Austin, Brach, & Wagner, 2009; Si, Bailie, & 
Weeramanthri, 2008; Stellefson et al., 2013). Information technologies, such as patient portals, 
provides an enhanced use of the CCM to facilitate improved delivery of chronic care management 
(Siminerio, 2010). 
Patient portals represent a component of electronic health records (EHRs) that provide 
direct access to health information and provider communication outside of the office visit. 
Healthcare organizations often adopt portals as a strategy to more effectively engage patients and 
deliver patient-centered care. Patients also expressed growing interest in portal use as 
demonstrated by increasing numbers of patients who register for these programs (Patel & Johnson, 
2018). A recent study revealed that approximately one-third of patients with T2DM had adopted 
the portal, which is slightly higher than what is observed in the general population. The advantages 
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associated with using this technology include increased awareness of health conditions, facilitated 
communication and access to care between visits, and promotion of behavioral change (Sun et al., 
2018). The increasing attractiveness of patient portals among individuals with diabetes and the 
potential capability of these portals to support and facilitate diabetes self-management necessitates 
an examination of portal effectiveness. 
Prior interventional studies have found inconsistent results regarding the effect of patient 
portals on glycemic control (Grant et al., 2008; Ralston et al., 2009; Tang et al., 2013; Vugt et al., 
2016). The portals used in these studies functioned as part of established diabetes management 
programs, and few studies examined the effect of a portal on diabetes-related outcomes in a real-
world setting. Several observational studies demonstrating efficacy of real-world portals offered 
as part of the integrated health system are limited by their cross-sectional design (Harris et al., 
2009; Shimada et al., 2016; Tenforde et al., 2011). There are currently no longitudinal studies that 
examine changes of HbA1c over time between portal users and non-users in patients with diabetes. 
4.3 METHODS 
4.3.1  Design 
This study was a 2-year retrospective cohort study using data from the EHR of the 
University of Pittsburgh Medical Center (UPMC) Physician Services. The University of Pittsburgh 
Institutional Review Board (IRB) approved the study 
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4.3.2  Setting and Sample 
The study cohort included 38,399 patients with T2DM who were seen in outpatient settings 
of the UPMC from January 2015 to December 2016. The selection process for this cohort was 
detailed in the previous study. Briefly, this cohort was derived from ongoing consumers of 
healthcare from UPMC who had a date of noted diabetes on the EHR problem list before the study 
began (January 1, 2015). Patients were excluded if they were new to the portal during the study 
period. Because this study focused only on patients with uncontrolled diabetes based on HbA1c 
values ≥ 7%, those with initial HbA1c values < 7% during the 2-year study period were excluded. 
To longitudinally examine the association of portal use and HbA1c, only data from patients with 
two or more HbA1c assessments were included for analysis. Therefore, 18,508 patients were 
eligible for this study, whether or not they use the portal. 
 UPMC patient portal, also known as MyUPMC, has been available for patients since 2007. 
This web-based portal enables patients to access part of their health information from the EHR, 
including a medical summary (e.g., immunizations, medications), laboratory results, and after visit 
summaries. Individuals can also manage appointments, renew prescriptions, pay bills, and securely 
communicate with their healthcare providers through the portal. 
4.3.3  Measures 
Patients’ demographic data, including age, gender, race (white, non-white), primary health 
insurance (Medicare, Commercial, Other), and 5-digit zip code, were collected from the EHR. 
Using the patient’s zip code, we estimated neighborhood variables from the U.S. Census Bureau’s 
2011-2015 American Community Survey (5-year estimate), including median household income, 
educational attainment (percentage of residents who had bachelor’s degree and above), and 
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urbanization (percentage of residents within an urbanized area within the zip code) (US Census 
Bureau, 2015). 
Outpatient visit data of each patient were collected, from which we identified whether or 
not the patient visited an endocrinologist within the 2-year period. The height and weight of each 
patient were recorded repeatedly at each clinic visit. The mode value of the height measures and 
the median value of weight were used to calculate the body mass index (BMI, kg/m2) using the 
formula (weight in pounds*703) / (height in inches)2.  
Medication data obtained included the generic name of the medication and the date of 
prescription. The American Hospital Formulary Services (AHFS) Pharmacologic-Therapeutic 
Classification System was utilized to identify anti-diabetic agents and all types of insulin 
(American Society of Health-System Pharmacists, 2016). The total number of distinct glucose-
lowering medications over the 2-year period was calculated. Insulin use was treated as a binary 
yes/no variable indicating whether or not the patient used insulin.  
HbA1c was measured when the tests were performed during the 2-year period and reflects 
the mean glycemia over the previous 8 to 12 weeks. The date of HbA1c assessments and the test 
result values were extracted directly from laboratory test results in the EHR. Time was treated as 
a continuous variable indicating the number of days elapsed between the date of the HbA1c 
assessment and the first day of the study period (i.e., January 1, 2015). When two or more HbA1c 
tests were performed less than two weeks apart, only the first measurement of HbA1c was kept in 
our analysis because 1) HbA1c is an indicator of average glucose in the past 8 to 12 weeks and 2) 
the HbA1c values measured within a short time span in our study were often close or identical. 
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4.3.4  Statistical Analysis 
Statistical analyses were performed using R statistical packages (R version 3.5.1 and R 
Studio 1.1.456). We assessed differences between portal users and non-users using the Mann-
Whitney U-test for continuous variables with skewed distributions and the Chi-square test of 
independence for categorical variables, with two-sided statistical testing and the level of statistical 
significance set at 0.05.  
We applied propensity score matching (PSM), a statistical matching approach that mimics 
randomized controlled trials and attempts to estimate treatment effects for causal inference 
(Rosenbaum & Rubin, 1983). PSM aims to balance the measured covariates across the treatment 
and the comparison groups. This approach is useful when estimating a treatment’s effect on an 
outcome using observational data and when randomization of patients to treatment groups is not 
possible or ethical (M. M. Garrido et al., 2014).In our study, we used this approach to remove bias 
associated with the differences in the observed patient characteristics between portal user group 
and the non-user group. We calculated propensity scores using a binary logistic regression model 
and a robust selection of independent variables to estimate the probability of patient portal use. 
The variables considered when estimating the propensity scores were factors associated with 
glycemic control, including demographic and socioeconomic factors (age, gender, race, health 
insurance type, and neighborhood household income, educational level, and urbanization based on 
the patient’s zip code) and clinical characteristics (BMI, number of HbA1c tests, initial HbA1c 
value, number of distinct glucose-lowering medications, insulin use, and any visit a UPMC 
endocrinologist). The nearest neighbor one-to-one matching approach was used (Austin, 2011a). 
Patients who were portal non-users were matched to those portal users on the logit of the propensity 
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score. A caliper of width equal to 0.2 of the pooled standard deviation of the logit of the propensity 
score was used that eliminated 99% of the bias due to the measured confounders (Austin, 2011b). 
We compared the change in HbA1c over time between the propensity-matched groups of 
portal users and non-users by fitting a linear mixed-effects model in the R package using lme4 for 
mixed models. We treated portal groups (portal users vs. non-users), time (linear and quadratic), 
and the interaction between group and time as the fixed effects. To account for variability in the 
patient-specific changes in HbA1c over time, random effects for intercepts and slope for each 
patient were included in the model. We removed the random quadratic effect of time for subject 
due to the convergence issue when being included in the model. To reduce the multicollinearity 
and different scaling issues among variables, time was standardized by subtracting the mean and 
then divided by the standard deviation (SD) ([time-mean]/SD). Non-significant effects were 
eliminated to achieve parsimonious models. Health insurance was included as a covariate due to 
the unadjusted difference between portal users and non-users after matching. A visual inspection 
of the residual plots did not reveal deviations from homoscedasticity and normality. 
4.4 RESULTS 
The final cohort consisted of 15,528 patients with initial HbA1c > 7%; 5198 (33.5%) of 
whom used the portal and 10,330 (66.5%) who did not. The majority of patients were white 
(85.9%), male (52.5%), and used public insurance (51.6% Medicare), with a mean age of 62.8 (SD 
11.7) years and BMI of 34.2 kg/m2 (SD 7.2 kg/m2). The neighborhood-estimated variables linked 
to each patient via their zip code demonstrated an average median household income of $51,106 
(SD $16,478) and on average 28.6% (SD 14.1%) had a bachelor’s degree or higher; and 79.2% 
(SD 30.5%) represented an urban population. On average, patients were prescribed 2.1 (SD 1.1) 
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distinct anti-diabetic medications and had received 3.4 (SD 1.2) HbA1c assessments during the 2-
year study period with initial HbA1c of 8.5% (SD 1.5%). 
The propensity score-matched cohort included 9848 patients: 4924 portal users and 4924 
non-users (Table 7). Before matching, portal users varied from non-users on a number of 
characteristics. Patients who used the portal were more likely to be younger (p < 0.001), white (p 
< 0.001), commercially insured (p < 0.001), and resided in zip codes having greater education 
attainment (p < 0.001), having higher median incomes (p < 0.001), and being more urban (p 
<0.001). Additionally, portal users overall had a higher on average median BMI (p < 0.001) and 
had more frequent HbA1c assessments (p = 0.001) with a lower mean initial HbA1c (p < 0.001), 
and had visited a UPMC endocrinologist (p < 0.001). After propensity score matching, patient 
characteristics in both groups were similar except for the type of health insurance (p < 0.001). 
Portal users tended to be insured with commercial products more than non-users. 
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Table 7. Comparison of Demographic and Socio-economic Neighborhood Characteristics of Portal Users and 
Non-users Before and After Matching 
 Unmatched Cohort Matched Cohort 
 Portal user 
(n=5,198)  
Mean ± SD/ 
n(%) 
Portal non-
user 
(n=10,330) 
Mean ± SD/ 
n(%) 
P Value Portal user 
(n=4,924) 
Mean ± SD/ 
n(%) 
Portal non-
user 
(n=4,924) 
Mean ± SD/ 
n(%) 
P Value 
Age, years 60.15 ± 10.90 64.06 ± 11.91 <.001 60.53 ± 10.75 60.54 ± 12.01 .762 
Gender    .057   .505 
Female 2413 (46.4) 4962 (48.0)  2284 (46.4) 2251 (45.7)  
Male 2785 (53.6) 5368 (52.0)  2640 (53.6) 2673 (54.3)  
Race   <.001   .336 
White  4675 (89.9) 8658 (83.8)  4404 (89.4) 4433 (90.0)  
Non-white 523 (10.1) 1672 (16.2)  520 (10.6) 491 (10.0)  
Insurance    <.001   <.001 
Medicare 2127 (40.9) 5891 (57.0)  2057 (41.8) 2331 (47.3)  
Commercial 2655 (51.1) 3272 (31.7)  2475 (50.3) 1945 (39.5)  
Othera 416 (8.0) 1167 (11.3)  392 (8.0) 648 (13.2)  
Educationb 31.93 ± 14.93 26.89 ± 13.36 <.001 31.04 ± 14.35 30.81 ± 14.51 .291 
Household 
income,b 
median 
55,329 ± 
18,167 
$48,981 ± 
$15,136 
<.001 $54,145 
($17,034) 
$53,713 
($17,130) 
.103 
Urbanizationb 82.22 ± 27.69 77.66 ± 31.65  <.001 81.61 ± 28.19 81.40 ± 27.98 .320 
BMI (kg/m2), 
median 
34.84 ± 7.10 33.89 ±7.19 <.001 34.74 ± 7.06 34.84 ± 7.45 .863 
# of HbA1c 
tests 
3.42 ± 1.20 3.35 ± 1.20 .001 3.33 ± 1.15 3.40 ± 1.24 .080 
Initial HbA1c 
value 
8.32 ± 1.38 8.53 ± 1.59 <.001 8.34 ± 1.40 8.34 ± 1.39 .894 
# of distinct 
DM 
medications 
2.16 ± 1.12 2.04 ± 1.08 <.001 2.13 ± 1.11 2.14 ± 1.14 .833 
Insulin use   .214   .952 
Yes 2385 (45.9) 4631 (44.8)  2232 (45.3) 2235 (45.4)  
No 2813 (54.1) 5699 (55.2)  2692 (54.7) 2689 (54.6)  
Any visit to an 
endocrinologist 
  <.001   .962 
Yes 1264 (24.3) 1959 (19.0)  1136 (23.1) 1138 (23.1)  
No 3934 (75.7) 8371 (81.0)  3788 (76.9) 3786 (76.9)  
Note. BMI, body mass index; DM, diabetes mellitus. 
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In the propensity score matched cohort, patients (n=4,924) with HbA1c > 7% in the portal user 
group showed a median usage of 32 login days with an interquartile range of 44 days during the 
2-year study period (Figure 6). When examining the frequency of access to each portal feature,
viewing the medical summary was used most frequently accounting for 38.3% of all portal access 
events, and followed by viewing laboratory results (24.6%), secure messaging (14.1%), managing 
appointments (11.3%), updating and sharing medical information (8.8%), and renewing 
medication prescriptions (3.0%) (Figure 7).  
N
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Figure 6. Histogram of Number of Login Days for Portal Users 
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An examination of patient portal use on glycemic control in the propensity score-matched 
group demonstrated significant group-by-time interaction (p < 0.001), group effect (p = 0.009), 
and linear and nonlinear time effect (all p < 0.001) on HbA1c (Table 8). Both groups showed a 
non-linear decline of HbA1c over time, with a greater decline in portal users compared to the non-
users. A slight rise was observed in both groups, with an earlier and larger increase observed 
among portal non-users (Figure 8). 
Manage 
appointments
11.3%
View medical 
summary
38.3%
Update and share medical 
information
8.8%
Renew 
prescriptions
3.0%
View lab results
24.6%
Secure 
messaging 
14.1%
Figure 7. Percentage of Accesses for Each Portal Feature 
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Table 8. Final Linear Mixed-effect Model for HbA1c in the Propensity-matched Cohort 
Fixed effects Estimate Standard error 
(SE) 
P values 
Portal use -0.063 0.025 .010** 
Time, standardized days -0.035 0.008 <.001*** 
Portal use*Time -0.068 0.012 <.001*** 
Time2 0.067 0.006 <.001*** 
Health insurance 
Medicare Reference 
Commercial 0.240 0.026 <.001*** 
Other 0.688 0.042 <.001*** 
Note. Time was measured by subtracting the first day of the study from the 
HbA1c assessment date. 
Legend: The x-axis standardized days is the z scores calculated based on the mean and the standard 
deviation of time measured in days; a standardized day of 0 equals to the mean days of HbA1c 
assessments (253.3 days) from the first day of the study. The standardized days of -2, -1, 1, 2 
represent how many standard deviations (SD 146.5 days) below (negative values) or above 
(positive values) the mean days.  
H
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Portal non-user 
Portal user 
Standardized Days 
Figure 8. Predicted HbA1c Over Time (Standardized Days) by Portal Use Groups 
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4.5 DISCUSSION 
This study extends results from previous cross-sectional investigations of patient portal use 
by longitudinally examining changes in glycemic control over time in patients with T2DM who 
do and do not engage in this technology. Our results from applying linear mixed-effects modeling 
revealed that patients who used the portal had a greater decrease of HbA1c over time, and this 
decrease was better maintained among portal users compared to the non-users over the 2-year 
study period.  
There are several possible explanations for the greater decline in HbA1c that we observed 
among portal users. First, patients with diabetes in one study reported the benefits of using patient 
portals, including engaging them in self-care through tracking their disease and improving 
awareness of their health status (Urowitz et al., 2012). Such patient engagement with chronic 
illness self-care is an important strategy that leads to positive health outcomes (Greene & Hibbard, 
2012). Second, patients who registered and logged onto the portal tended to have a higher level of 
engagement with managing their diabetes than those who did not use the portal. These individuals 
may have been more proactive in seeking healthcare services and were more likely to learn about 
their health conditions through other forms of media in addition to the portal. Finally, patient portal 
use of an online refill function may result in enhanced medication adherence among patients with 
diabetes, as a previous study has demonstrated (Sarkar et al., 2014). 
Prior studies using cross-sectional data from EHRs examined certain features (i.e., secure 
messaging, refill prescription) within the portal and its association with glycemic control. An 
earlier study of 15,427 patients found that 12 or more threads of message exchange between 
patients and providers over a period of 14 months were associated with better glycemic control 
(HbA1c < 7%, relative risk [RR] 1.36, 95% CI: 1.16–1.58) (Harris et al., 2009). A study by 
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Shimada et al. demonstrated that patients with two or more years of secure messaging use, but not 
online medication refill use, were more likely to achieve glycemic control three years later at 
follow up (Shimada et al., 2016). Only one study examined the association of the overall portal 
use with diabetes specific measures, including HbA1c. The results demonstrated a slight decrease 
in HbA1c (0.02%, p < 0.01) associated with a 10-day increase of portal use (Tenforde et al., 2011). 
These studies support the use of patient portals for improving clinical outcomes in patients with 
diabetes. 
Although we observed statistically significant HbA1c change over time, the clinical 
significance needs to be evaluated given the sufficient power of detecting differences due to the 
very large sample. According to Khaw et al., a 0.1% decrease of mean HbA1c could prevent 12% 
of the excess death, and a 0.2% decrease of HbA1c lowered the all-cause mortality by 10% (Khaw 
et al., 2001). Thus, our results are meaningful in practice, although greater improvements are 
desirable.  
 Despite the number of studies demonstrating efficacy of portal use on A1c in patient 
populations with diabetes, major disparities in using this information technology exist.  These 
include unawareness of portals or their efficacy, lack of access due to educational issues or 
socioeconomic status, or lack of buy-in on the part of physicians who may see this as a source of 
non-reimbursable care fee for service settings (Sun et al., 2018). It will be important to address 
existing barriers to portal use among both patients and providers in the future. Interventions 
targeting increased awareness of, access to, and physician involvement in using these tools have 
potential to not only improve care delivery but also guiding patients to take better care of their own 
health. 
Several strengths of this study need to be recognized. We examined the patient portal use 
over time in a real-world setting offered by an integrated health system. Our study was the first 
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longitudinal investigation of the effect of a patient portal on glycemic outcomes in a large sample 
of patients with T2DM. The use of a propensity score matching approach allowed us to infer causal 
inference through balancing patient socio-demographics (e.g., age, gender, race, education) and 
clinical characteristics (e.g., the number of HbA1c assessments, any visit to an endocrinologist).   
This study also has several limitations. Distinct from randomized controlled trials, where 
the intervention and the control group are balanced on both the observed and unobserved/latent 
variables through randomization, PSM allows matching only on observed variables associated 
with the outcome as identified from theory or literature. This may interfere with the ability to 
obtain balance on other unobserved/latent variables (M. M. Garrido et al., 2014). In addition, 
baseline HbA1c values before entering the study were not collected; instead, a patient’s initial 
HbA1c value during the 2-year period was used as the baseline blood glucose level to balance 
portal users and non-users. Other limitations were associated with the inaccuracies and incomplete 
EHR data. Diabetes diagnosis dates that appeared on the problem list underestimated the duration 
of patient diabetes when compared to other studies using data from similar sources. Some patients 
performed point-of-care HbA1c testing during a clinic visit; however, the results of those 
assessments were not available in the outpatient EHR. Moreover, we were unable to track patient 
data if they visited another healthcare system that is not comparable to the current EHR system. 
Lastly, it is important to note that we were unable to track in the EHR behavior change and self-
efficacy for managing diabetes, or whether or not the patients took their medications or filled or 
refilled the prescription. These limitations are similar to those of many other studies using EHR 
data. 
These findings highlight the significance of patient portals as a promising technology for 
engaging patients and enhancing clinical outcomes in patients with diabetes who are seeking to 
optimize their glycemic control. Future research is needed to reveal the underlying mediating 
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mechanisms that may contribute to the improved glycemic control as well as other outcomes. Some 
portal features may be more important than others in assisting patients to manage their conditions; 
these features need to be identified to provide an evidence-based portal design and implementation. 
Clinicians and researchers need to identify strategies to ensure the sustained use of the portal and 
encourage those who have not begun using the portal to sign up for access and use of the portal.  
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Appendix A TABLES OF OBSERVATIONAL STUDIES EXAMINING PATIENT 
PORTALS FOR DIABETES MANAGEMENT 
Observational Studies Examining Patient Portals for Diabetes Management 
Authors and  
country 
Study aims, 
design, and  
level of evidence 
Sample Portal features Outcomes 
(portal-related) 
Results  
Shimada et al 
(2016), 
US  
 
5-year 
retrospective 
cohort study to 
examine the 
association of 
secure messaging 
(SM) use and 
Web-based 
prescription 
refills use with 
physiological 
measures among 
Patients (Ps) with 
type 2 diabetes 
mellitus (T2DM) 
 
Evidence: Grade 
B 
N=111,686; user 
45.2%; females: 
3.6%; white: 
68.9%; age 62.1 
(SD 9.6) years 
 
 
My HealtheVet by 
Department of Veterans’ 
Affairs allows Ps to: 
1) enter data for diet, 
activity, and vital signs 
2) set goals 
3) access data from 
electronic health record 
(EHR) 
4) communicate with 
providers 
5) request prescription 
refills 
 
HbA1c, low-
density 
lipoprotein 
(LDL), blood 
pressure (BP), 
SM use, and 
prescription 
refill use 
34.1% of the sample used refill 
and 15.8% used SM. Users 
were younger (P<.001), and 
more likely to be female 
(P<.001). Ps with uncontrolled 
glucose were more likely to 
achieve glycemic control after 
≥2 year of SM use. Ps with 
uncontrolled BP were more 
likely to achieve BP control 
after ≥2 years of refill use. No 
association of refill use with 
glycemic control were noted. 
Both features were associated 
with lower LDL at follow-up.  
Ronda et al 
(2015), 
Netherlands  
Survey study of 
Ps with diabetes 
mellitus (DM) to 
understand their 
experiences with 
a web portal 
 
Evidence: Grade 
C 
N=632; T2DM: 
81.8%; males: 
63.1%; white: 
92.8%; age 59.7 
(SD 13.2) years; 
HbA1c: 7.2% 
Digitaal Logboek 
(diabetes mellitus [DM]-
specific) by Diamuraal 
allows Ps to: 
1) access data from 
EHR 
2) review medication 
list 
3) receive diabetes 
education 
4) view examinations 
and a visit summary 
4) upload glucose 
remotely 
5) message providers 
login 
frequency, 
perceived 
usefulness, and 
diabetes 
knowledge 
Insulin use (odds ratio [OR] 
2.07), frequently experiencing 
hyperglycemic episodes (OR 
1.30), and better diabetes 
knowledge (OR 1.02) increases 
the odds of being a persistent 
user (≥2 times). Early quitters 
(n=219) felt items were not 
applicable to their situation. Ps 
prefer a reminder function and 
including medication 
information and side-effects. 
Ronda et al 
(2014),  
Netherlands   
Survey study of 
Ps with DM on 
their opinions 
and the barriers 
to requesting a 
login and to 
using a portal 
 
Evidence: Grade 
C 
N=1,390; T2DM: 
77.5%; 
regular use 
(n=632) vs. 
nonuser (n=758);  
males: 
62.7% vs. 56.5%; 
Caucasian: 
93.6% vs. 89.3%; 
age: 
Digitaal Logboek (DM-
specific) by Diamuraal 
allows patients to: same 
as above 
self-reported 
usage, reasons 
for requesting 
or not 
requesting a 
login, how 
they heard of 
the portal, 
frequency and 
duration of 
14% were nonusers among Ps 
with type 1 diabetes mellitus 
(T1DM) compared to 69.2% 
among Ps with T2DM. 
The main reason for not using 
was unawareness (72.4%). 
Younger age, higher education, 
being treated by an internist, 
insulin use, polypharmacy, 
better diabetes knowledge, and 
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60.2 vs. 68.1 
years; 
HbA1c:  
7.1% vs. 6.8% 
portal use, who 
helped add 
data to the 
portal  
more hyperglycemic episodes 
were associated with portal 
use. Nonusers perceived 
specific portal content as less 
useful. 
Roelofsen et al 
(2014),  
Netherlands   
Cross-sectional 
study to explore 
the differences in 
Ps with T2DM 
who were 
interested and 
uninterested in 
the portal  
 
Evidence: Grade 
C  
N=1,378; 
Interested 
(n=974) vs 
uninterested 
(n=404); 
males: 
56.6% vs. 48.5%; 
age: 62.3 (SD 
9.7) vs. 68.4 (SD 
9.7) years; 
body mass index 
(BMI): 29.8 (SD 
5.0) vs. 30.2 (SD 
5.5) 
e-Vita (DM-specific) by 
the Diabetes Center in 
Zwolle allows Ps to:  
1) receive messages 
2) review checkup 
results 
3) set goals and actions 
4) monitor metabolic 
values 
5) receive education 
Usage Of the 974 Ps who interested in 
the portal, 405 (41.6%) were 
registered for it, and 110 
(27.2%) actually logged on to 
the portal. Interest Ps were 
more likely to be male, 
younger, higher educated, and 
have shorter T2DM duration.  
Sarkar et al 
(2014), 
US  
 
Observation 
cohort study to 
determine the 
statin adherence 
before and after 
using the refill 
function in the 
portal between 
2006 and 2010 
 
Evidence: Grade 
B 
N= 17,760 
males: 54%; 
white: 58%; 
age: 62.7 (SD 11) 
years 
Web-based portal kp.org 
by Kaiser Permanente 
Northern California 
(KPNC) allows Ps to: 
1) request medication 
refills 
2) view medical history 
and office visit 
summary 
3) view laboratory 
results 
4) schedule 
appointments 
5) message providers 
Statin 
adherence, 
LDL, use of 
refill function 
49% (n=8,705) of the cohort 
used the refill. LDL decreased 
by 3.1 mg/dL among exclusive 
users (i.e. request all statin 
refills on the Web) than 
nonusers. Nonadherence 
declined by 6% (95% 
confidence interval [CI]: 4%–
7%) among exclusive users, 
without changes among 
occasional users (request refills 
on the Web as least once). No 
differences were identified 
between occasional users and 
non-users. The improvement in 
LDL was partially mediated by 
improved adherence.  
Sieverink et al 
(2014),  
Netherlands   
Descriptive study 
to understand the 
usage pattern of 
the first 6 weeks 
using the 
personal health 
record (PHR) by 
patients with 
T2DM 
 
Evidence: Grade 
C 
N=568  e-Vita (DM-specific) by 
the Diabetes Center in 
Zwolle allows Ps to: 
same as above 
Number of 
logins, time 
and day of the 
action, actions 
taken, 
information 
reviewed, and 
goals added 
28% of all registered users 
(n=161) visited e-Vita at least 
once in the first 6 weeks, the 
number declined over the 
weeks. 93% of users ended 
their session the first time they 
visited the education session. 
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Lyles CR, et al 
(2013),  
U  
Survey design to 
examine the 
association 
between patient-
provider 
communication 
or trust ratings 
and 1) being a 
registered user 
and 2) use of SM 
 
Evidence: Grade 
C 
N=14,102; 
males: 51%; 
white: 33%; 
age≥ 60 years: 
50%  
Web-based portal by 
KPNC allows Ps to: same 
as above 
Portal use in 
the 2 years 
during or 
following 
survey 
completion 
(2006–2007), 
secure 
message use, 
communicatio
n, trust 
36% of the user used 
messaging. Increased trust was 
associated with being a 
registered user among white, 
Latino, and older Ps, as well as 
SM use among white Ps. Better 
communication ratings were 
related to being a registered 
user. 
Ronda et al 
(2013),  
Netherlands  
Survey study 
design to 
examine the 
differences of Ps 
with and without 
a login by DM 
type 
 
Evidence: Grade 
C 
N=1,390; T1DM: 
9.2%; 
males: 59.4%; 
age: 63.9 (SD 
12.2) years; 
response rate: 
67% 
Digitaal Logboek (DM-
specific) by Diamuraal 
allows patients to: 
1) access data from 
EHR 
2) receive general 
diabetes education 
3) view all 
examinations and 
diabetes visits 
4) upload glucose level 
remotely 
5) contact with care 
provider 
Diabetes 
treatment 
satisfaction, 
diabetes-
specific 
distress, 
general well-
being, diabetes 
management 
self-efficacy, 
and diabetes 
knowledge 
Among 128 Ps with T1DM, 
those with a login (89.8%) 
were younger, had better 
diabetes knowledge, and 
treated by an internist. In 1,262 
Ps with T2MD, fewer Ps had a 
log-in (41.0%), and having a 
login was associated with 
younger age, male, higher 
education, treatment by an 
internist, longer diabetes 
duration, and polypharmacy 
(all P<.001). Ps with a login 
perceived more diabetes-
related distress, more hyper- 
and hypo- glycemic episodes, 
more self-efficacy, and better 
diabetes knowledge. 
Tenforde et al 
(2011),  
US  
Retrospective 
audit of PHR use 
during July 
2008–June 2009 
to measure the 
association 
between PHR use 
and diabetes 
quality measures  
 
Evidence: Grade 
C 
N=10,746; 
user vs nonuser; 
females: 
46% vs. 50% 
(P<.01); 
white:  
84% vs. 66% 
(P<.01); 
age: 
59 (SD 10) vs. 62 
(SD 10) years 
(P<.01) 
Income: 
53,000 vs. 47,500 
(P<.01) 
MyChart by Cleveland 
Clinic allows Ps to: 
1) access data from 
electronic medical 
record (EMR)  
2) view glucometer 
readings 
3) access diabetes 
education  
4) receive reminders 
for diabetes-related 
tests 
5) communicate with 
providers   
HbA1C, LDL, 
BP, BMI, 
ACEi/ARB 
use and/or 
microalbumin 
testing, 
pneumococcal 
vaccination, 
foot and 
dilated eye 
examination, 
and smoking 
status, PHR 
use 
Compared to non-users 
(n=6,710), PHR users 
(n=4,036) were younger, had 
higher income and education, 
tend to be Caucasian. PHR 
users had lower HbA1c (by 
0.29%), SBP (by 1.13 mmHg), 
and DBP (by 0.54 mmHg) (all 
P<.01). An incremental 
increase in PHR use days by 10 
was associated with greater 
odds of having decreased 
HbA1c values (0.02%, P<.01). 
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Bredfeldt et al 
(2011),  
US  
Retrospective 
study to 
determine 
whether 
interaction with 
physician 
between office 
visits provide 
better care during 
January 2007–
December 2008 
 
Evidence: Grade 
C  
N=174 primary 
care physician 
(PCPs); Ps panels 
that are white or 
mixed race vs. 
black or 
Hispanic: 
age: 
57.8 (SD 2.3) vs. 
57.9 (SD 2.5) 
years; 
Income:  
$90,359 vs. 
$60,499  
MyChart by Kaiser 
Permanente, Mid-
Atlantic States allows Ps 
to: 
1) access laboratory 
and pharmacy 
information  
2) schedule 
appointments 
3) communicate with 
physicians 
  
Diabetes 
Recognition 
Program 
(DRP) score, 
use of 
messaging and 
number of 
phone calls 
Physicians (n=116) whose Ps 
were white or mixed race tend 
to use more messaging and 
phone with their Ps between 
visits. No association between 
such contacts and DRP scores 
was noted. Physicians (n=58) 
with black or Hispanic Ps had 
higher DRP scores associated 
with the messaging (P<.01).  
Sarkar et al 
(2011), 
US  
 
Survey method 
to examine Ps 
use patterns of 
the kp.org by 
patients with DM 
during January– 
December 2006 
 
Evidence: Grade 
C 
N=14,102;  
females: 49%; 
non-white: 78%; 
age: 50-59 33%; 
HbA1c: 7.59%; 
kp.org by KPNC 
allows Ps to: 
1) view lab results  
2) communicate with 
providers  
3) request medication 
refills 
4) schedule 
appointment 
Proportion of 
Ps who 
activated 
accounts, 
logged on, and 
use of health-
services 
functions 
40% of the 14,102 Ps requested 
a password for the portal. Of 
these, 4311 (76%) activated the 
accounts, and 69% logged on; 
53% viewed laboratory results, 
38% requested medication 
refills, 37% sent messages, and 
15% made appointments. 
African-Americans and 
Latinos had higher odds of 
never logging on (OR 2.6; OR 
2.3) compared to non-Hispanic 
Caucasians, as did those 
without an educational degree 
(OR 2.3).  
Cho et al  
(2010),  
US  
Cross-sectional 
survey to 
measure 
veterans' access 
to and use of the 
Internet, and 
their interest in 
using the portal 
for T2DM 
 
Evidence: Grade 
C 
N=201; males: 
97%; white: 
60%; age: 58.9 
(SD 10.4); 
HbA1c: 9.6% 
My HealtheVet by 
Department of Veteran 
Affairs Medical Center 
allows Ps to: 
1) access EHR data 
2) enter medications, 
glucose and BP 
readings 
3) request prescription 
refills 
4) access provider 
notes 
5) receive reminders 
6) message providers 
Awareness and 
current use of 
the Web portal, 
and interest in 
using it to 
manage 
diabetes 
41% are very interested in 
using MHV to track blood 
glucose readings at home. A 
third did not have access to 
internet at home. Factors 
associated with being very 
interested were: having internet 
access at home (P<.001), "a 
lot/some" trust in the Internet 
as a source of health 
information (P=.002), younger 
age (P=.03), and some college 
(P=.04).  
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Sarkar et al 
(2010),  
US  
Survey study 
design to 
investigate use of 
an internet-based 
patient portal 
among adults 
with DM during 
January–
December 2006 
 
Evidence: Grade 
C 
N=14,102; 
females: 49%; 
non-white: 78%; 
age: 50-59 33%; 
HbA1c: 7.59% 
Patient portal by KPNC 
allows Ps to: same as 
above 
Health literacy, 
use of each 
feature in the 
portal 
40% (n=5,671) registered, 76% 
(n=4,311) logged in. The pages 
visited were view laboratory 
results, request medication 
refills, send messages to 
providers, and make 
appointments. People with 
limited health literacy had 
higher odds of never signing on 
to the portal (OR 1.7, 95% CI 
1.4–1.9).  
Weppner et al 
(2010), 
US   
Retrospective 
cohort study to 
describe use of a 
web-based 
shared medical 
record (SMR, 
MyGroupHealth) 
by older patients 
with DM during 
August 2003–
August 2007 
 
Evidence: Grade 
B 
N=6,185; 
females: 50.9%;  
age: 75.2 (SD 
6.7) years 
MyGroupHealth by 
Group Health 
Cooperative allows Ps to: 
1) view EHR data  
2) request medication 
refills 
3) make appointments 
4) communicate with 
providers 
Initial use, 
subsequent 
use, PCP's use 
of the 
communicatio
n feature 
32.2% (n=1,990) used the 
SMR. Portal use was 
associated with younger age, 
male, and higher 
socioeconomic status, overall 
morbidity, and PCP's use. SMR 
use was more likely within 3 
months of an increase in 
morbidity (hazard ratio 1.61, 
95% CI 1.28–2.01) and within 
1 month of changing to a PCP 
with higher SM use (hazard 
ratio 3.02, 95% CI 1.66–5.51). 
Harris et al 
(2009), 
US 
  
Cross-sectional 
analysis to test 
the association of 
electronic 
messaging with 
care quality for 
DM or outpatient 
utilization 
between January 
2004–March 
2005 
 
Evidence: Grade 
C 
N=15,427 
 
 
   
MyGroupHealth by 
Group Health 
Cooperative allows Ps to: 
same as above 
HbA1c, BP, 
LDL, 
outpatient 
visits, use of 
electronic 
messaging 
34% (n=5,274) registered the 
portal, and 19% of Ps 
(n=2,924) used electronic 
messaging. Frequent use of 
electronic messaging (i.e.≥12 
threads) was associated with 
A1C<7% (RR 1.36, 95% CI 
1.16–1.58), a higher rate of 
outpatient visits (RR 1.39, 95% 
CI 1.26–1.53), but not BP. 
Small but significant 
association was observed 
between secure messaging and 
LDL<100 mg/dl.  
Wald et al 
(2009),  
US   
Survey design to 
examine patient 
journal use and 
patient 
experience using 
the diabetes 
journal by Ps 
with T2DM 
during 2005–
2007 
 
Evidence: Grade 
C 
N=126; males: 
58%; white: 
93%; age: 59.4 
years; 
HbA1c<7.0%: 
60%; 
response rate: 
67% 
Patient Gateway by 
Partners Health care 
allows Ps to:  
1) access data from 
EHR  
3) enter concerns and 
requests about glucose, 
cholesterol, and BP 
control 
4) request for referrals 
or education 
5) change medication 
and allergy list   
Use of the 
electronic 
journal, journal 
experience  
A diabetes care plan took 5–9 
minutes to complete by the 
patient. 61% reported they 
talked with their provider about 
their journal information and it 
helped Ps feel more prepared 
for their visit (60%) and 
provide more information to 
provider (53%).  
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